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Cell s respond to hormonal, neurochemi cal and nutri ti onal si gnal s by ad­
j usti ng thei r metabol i c and bi osyntheti c machi nery. Some of these responses
are mediated by effector proteins which regulate various enzymes. Several
cal ci urn modul ated protei ns are effector protei ns whose regul atory acti vi ti es
are modulated by fluctuations in the intracellular free calcium ion concen­
trati on. These cal ci urn modul ated effector protei ns are i nv_ol ved in fundamen­
tal cell ul ar processes such as gl ucose metabo1 ism, musc1 e contracti on, cell
motil i ty, secreti on, and mi tos is. The experi ments presented in th is thes is
are part of an effort to compare the bi ochemi cal, immunochemi cal and phar­
macological properties of several calcium modulated effector proteins. An
understanding of the molecular physiology of calcium modulated proteins
provides the foundation for elucidating the mechanisms of calcium action in
cellular physiology.
Effector Proteins
A vari ety of enzymes employ regul atory effector protei ns whi ch modul ate
the enzymatic response to external stimuli. These enzymes include protein
k i nases (1-2), adenos i ne tri phosphatases (3), acetyl coenzyme A carboxyl ase
(4), fatty acid synthetase (4-6), and lactose synthetase (7-9). Although
these enzymes have diverse functions, their effector proteins form struc­
turally and functionally related classes of proteins.
The regul atory subuni t of the cycl i c adenosi ne monophosphate dependent
protei n kinase is an effector protei n whi ch bi nds cAMP, 1 eadi ng to its di s­
soci ati on from the catalyti c subuni t ( 1). The free catalyti c subuni t carri es
out the transfer of phosphate from ATP to speci fi c hydroxyl groups of protei n
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substrates. In thi s manner the regu1 atory subuni t medi ates the responses of
cell s to hormones whi ch cause changes in the i ntrace11 u1 ar cAMP 1 evel s , For
example, when p-adrenergic agonists stimulate cAMP production in
hepatocytes, the regulatory subunit transduces this signal into activation
of the protein kinase cascade involved in glycogen breakdown (2).
Another effector protein, a-lactalbumin, regulates the synthesis of
1 actose by mammary ti ssue (7). The enzyme gal actosyl transferase (UDP gal ac­
tose-N-acety1glucosamine-s -4-galactosyl transferase) catalyzes the con­
densati on of gal actose and gl ucose to form the di sacchari de, 1 actose (7). The
transferase requi res a-l actal bumi n to speci fy gl ucose as the substrate( 8-9) ,
and the 1 eve1 of a-l acta1 bumi n in the ti ssue hel ps to control the rate of 1 ac­
tose synthesis (7-9). Prolactin acts in conjunction with insulin and
steroids to induce a-lactalbumin synthesis in the mammary tissue of adult
females post partum (7).
The acyl carri er protei n (ACP) of fatty aci d synthetase is an effector
protein (5-6) which forms a covalent intermediate with the growing acyl
chain. Although other parts of the synthetase complex catalyze the addition
of two carbon uni ts to the growi ng acyl chai n, the acyl carri er protei n is es­
sential for proper enzymatic function (4). The prosthetic group, 41-phos­
phopantethei ne, is 1 inked through a phosphodi ester bond to the hydroxyl of a
seri ne res i due in the ACP (6). The level s of synthetase acti vi ty are linked to
the presence of the water soluble vitamin pantothenate in the diet (4).
Similarly, the biotin carboxyl carrier protein (BCCP) forms a covalent com­
p1 ex wi th bi oti n and acts as an accessory to the acetyl coenzyme A carboxyl ase
enzyme comp1 ex (4,10-11). The acti vi ty of the enzyme is dependent on bi oti n,
and citrate is an allosteric regulator of carboxylase activity (4).
Several cal ci urn modu1 ated protei ns are examp1 es of effector protei ns,
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each conferring calcium ion sensitivity on enzymes. Troponin C is a calcium
modulated effector protein which confers calcium sensitivity on the ac­
tomyosin ATPase of skeletal and cardiac muscle (3). Troponin C regulates
muscle contraction bymediating the flux of calcium ions stimulated by acetyl
choline release at the neuromuscular junction.
In smooth muscl e, two cal ci urn modul ated effector protei ns are i nvol ved
in regulating muscle contraction. The regulatory 1 ight chain of myosin is a
calcium modulated protein (12-13) which regulates the myosin ATPase (14).
Smooth muscle contraction may be regulated by phosphorylation of the light
chainbytheenzymemyosinlightchainkinase (15). This kinase is stimulated
by calcium and calmodulin (13,16-17), another calcium modulated effector
protei n. In 1; ver and stri ated muscl e, cal modul in; s an integral subuni t of
phosphoryl ase ki nase (18), and cal modul in al so acti vates glycogen synthase
kinase in liver (19), thus regulating both the breakdown and synthesis of gly-
cogen.
Hormones, neurotransmi tters, vi tami ns and drugs may affect the 1 evel of
messengers such as Ca
2+
or cAMP, wh i ch signal effector protei ns such as cal­
modul in and the regul atory subuni t of cAMP dependent protei n k; nase. A1 ter­
nati vely, the endocri ne stimul at; on of a cell may induce the synthesi s of an
effector protei n as in a-l actal bumi n. A thi rd category of effector protei ns
is exempl ified by ACP and BCCP which covalently 1 ink the dietary vitamins and
cofactors necessary for metabol i c functi ons. Of these categori es of effector
proteins, the calcium modulated effector proteins illustrate how




Calcium is required for optimal growth and functioning of most living
organi sms, and studi es of the mol ecul ar basi s of cal ci urn acti on i ndi cate that
proteins act as calcium ion receptors (12-13). Calcium binding proteins may
be di vi ded into four cl asses refl ecti ng di fferent ways in whi ch protei ns bi nd
and use cal ci urn. Fi rst, protei ns contai ni ng y-carboxygl utami c aci d bi nd cal­
cium through bidentate chelation. The proteins involved in blood clotting
such as prothrombi n (20) and Factor X (21) are the best characteri zed protei ns
containing y-carboxyglutamic acid. These proteins bind calcium with dis­
soci ati on constants in the mi 11 imol ar range, approximately the serum 1 evel s
of calcium (13,20-21). Second, certain proteins use calcium ions to
stabilize a particular conformation. Calcium binding lectins such as con­
canavalin A (22) and the calcium binding enzyme, thermolysin (23), use cal­
cium in paired divalent cation binding sites which appear to enhance the
stability of the protein. These proteins use mainly oxygen-containing side
chains of amino acids to form polyhedral calcium binding sites with rela­
tively high affinities for calcium. Third, calcium binding enzymes may use
cal ci urn ions in substrate bi ndi ng and enzymi c catalysi s . For exampl e, pan­
creatic phosphol ipase A2 contains a calcium binding site near the active site
of the enzyme (24). The bound calcium acts to stabilize the bound phos­
phol ipid substrate and to help catalyze the hydrolysis of the fatty acid gly­
cerol ester bond (25). The calcium ion in phospholipase A2 is mainly
coordi nated by pepti de carbonyl oxygens and water mol ecul es (24). Other hy-
drolytic enzymes such as trypsin, chymotrypsin and staphyloccocol nuclease
also contain calcium binding sites (13). Fourth, calcium modulated proteins
bind calcium reversibly at physiological ionic strength and pH with dissocia-
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tion constants in the micromolar concentration range (12-13). The calcium
bi ndi ng structures of cal ci urn modul ated protei ns are octahedral, empl oyi ng
oxygen-containing side chains as well as peptide carbonyl oxygens to
coordinate the calcium ion. Examples of calcium modulated proteins are
troponin C, parvalbumin, calmodulin, S100, myosin regulatory light chains,
and the vitamin 0 dependent calcium binding protein.
Kretsi nger (12) has proposed that protei ns whi ch contai n EF hand struc-
tures are the targets of calcium acting as a second messenger intracel-
1 ul arly. All cal ci urn moul ated protei ns for whi ch an ami no aci d sequence is
known contain potential calcium binding structures known as EF hand struc­
tures. The term EF hand is deri ved from the cal ci urn bi ndi ng structure in carp
parvalbumin for which the crystal structure has been determined. The EF hand
is formed by the E-a hel i x and the F-a hel i x connected by a pepti de loop. The
loop contains the amino acid residues which have the ligating oxygens of the
octahedral calcium site. In the EF hand region of carp parvalbumin, four of
the cal ci urn 1 i gands are formed by carboxyl ate moieti es of asparti c aci d and
glutamic acid side chains. One 1 igand, the -Y vertex of the octahedron, em­
ploys the oxygen of the pepti de carbonyl. In thi s case, there is no restri c­
tion on the nature of the side chain of the -Y amino acid (12). The sixth
1 i gand is a water mol ecul e whi ch i ntercal ates between the pepti de carbonyl of
a glycine residue and the calcium ion. All potential EF hand structures con­
tain amino acid sequence homol ogy with the parvalbumin EF hand region. In ad­
di ti on to the 1 i gati ng ami no aci ds, the presence of a glyci ne between the Y and
Z verti ces may be requi red to allow the pepti de loop to make a sharp bend whi 1 e
wrapping itself around the calcium ion.
Flanking the calcium binding loop are the two a helices, the E helix and
the F helix. These helices are amphipathic in nature because the side chains
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of resi dues on the inner faces of the hel ices are hydrophobi c, whi 1 e those on
the outer faces are generally hydrophi 1 i c. In the EF hand model of Kretsi nger
(12) , the hydrophobi c surfaces of the hel ices face the hydrophobi c core of the
protein. Pairs of EF hand structures may be stabilized by hydrophobic in­
teractions between hel ices as well as interactions between side chains of the
loops. However, it is not cl ear from the crystal structure of parval bumi n
(26) what generally determi nes how mul ti pl e pai rs of EF hand structures i n­
teract in proteins. Until the three dimensional structure of a protein with
four or more EF hand structures is known, the model is restri cted to uni ts of
two EF hands.
Ouri ng the. past decade the primary structures of several cal ci urn
modul ated protei ns have been determi ned (12-13,27-34). From muscl e
research, the pioneering experiments of Ebashi (3) led to the isolation of
troponin C and its identification as the calcium sensitizing subunit of ac­
tomyosin ATPase. Collins et al. (27) determined the complete amino acid se­
quence of the protein from rabbit skeletal muscle, and Van Eerd et ale (28)
determi ned the primary structure of bovi ne cardi ac troponi n C. Both of these
mol ecul es have four domai ns contai ni ng potenti al EF hand structures and have
internal amino acid sequence homology. The skeletal muscle troponin C binds
four mol es of cal ci urn per mol e of protei n whi 1 e the cardi ac troponi n C bi nds
only three (12). The 1 ack of one functi onal cal ci urn bi ndi ng domai n in cardi ac
troponi n C may be due to several ami no aci d substi tuti ons whi ch modify the EF
hand structure of the second domain (28).
Through another channel of research on muscl e protei ns, the regul atory
1 i ght chai ns of myosi n were shown to be cal ci urn modul ated protei ns (12-14).
Among vertebrates, light chains range from 16,000-21,000 molecular weight




The regul atory 1 i ght chai ns bi nd only one mol e of Ca
2+
per mol e of protei n
when associ ated wi th the myosi n heavy chai n (14), al though regul atory 1 i ght
chai ns contai n four domai ns wi th ami no aci d sequence homology to the EF hand
structure (12). Several amino acid changes and deletions in the non-binding
domai ns may account for the 1 ack of cal ci urn bi ndi ng functi on, as in the second
domain of cardiac troponin C (12,28). In addition, regulatory light chains
are phosphoryl ated at seri ne resi dues by the enzyme myosi n 1 i ght chai n kinase
(1,15-17). Hartshorne and Persechi ni (15) have suggested that phosphoryl a­
tion of the light chain regulates myosin ATPase activity in smooth muscle.
However, it is not cl ear how phosphoryl ati on of 1 i ght chai ns affect the cal­
cium binding properties of the potential EF hand structures.
Calciummodulated proteins are also found in non-muscle tissue (12-13).
the vi tami nO-dependent, cal ci urn bi ndi ng protei n from mammal ian i ntesti ne is
an acidic protein with Mr � 10,000 (13,29). Based on crystallographic studies
of the bovine protein (30) there is one region which contains an EF hand struc­
ture and bi nds one mol e of cal ct urn. In addi ti on, a second cal ci urn bi ndi ng si te
occurs in the ami no termi nal hal f of the protei n. Thi s si te is simil ar to EF
hand structure, but the exact nature of the 1; gat; ng speci es is st.i 11 under
i nvesti gati on. A second group of vi tami nO-dependent cal ci urn bi ndi ng
protei ns are found in the avi an i ntesti ne and mammal; an kidney (13,31). These
protei ns have Mr =28,000 (13,31). The structures of these larger vi tami n 0-
dependent protei ns have not been determi ned, but these protei ns may prove to
be an interesting type of calcium modulated proteins.
Brai n ti ssue has been a ri ch source of three cal ci urn modu1 ated protei ns:
calmodulin, S100a and S10013 (32-34). Because these proteins are the subject
of most of the studi es presented in thi s thesi s, it is i nstructi ve to exami ne
calmodulin, S100aand S10013 in detail. The isolation and characterization of
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Calmodul in is the name proposed (35) for a calcium binding protein which
was first purified to chemical homogeneity by Watterson et al. (36) as a
troponin C-like protein of bovine brain. Most eukaryotic cells contain cal­
modulin, and the amino acid sequence of calmodulin is highly conserved
(13,37). Vertebrate calmodulin is an acidic, calcium-binding protein con­
sisting of 148 amino acid residues. Bovine brain calmodulin contains no tryp­
tophan, cysteine, phosphate or carbohydrate (32,36) and contains one residue
of N E-trimethyllysine (32). Calmodul in has four structural domains that are
similar to each other and similar to the four domains of skeletal muscle
troponi n C (27 ,32). Each of the four cal modul in doma ins conta ins the requi re­
ments for a model EF hand structure (12-13), and the protein binds four moles
of calcium per mole of protein. The direct demonstration of the calcium
1 i gati ng speci es in the protei n will depend on data from the crystall ographi c
studies of Cook et al. (38) and Kretsinger et al. (39).
A compari son of the ami no aci d sequences of cal modul in from four speci es
is shown in Figure 1. The amino acid sequence studies of calmodulins from
various species indicate that vertebrate calmodul ins may be identical
(32,40-43). These species include bovine (32), human (40), chicken (41), rat
(42) and rabbi t (43). Nearly compl ete ami no aci d sequences have been deter­
mined for calmodulin from the invertebrates Renilla reniformis (44) and
Metridium senile (45). These proteins have several amino acid substitutions
from the bovine brain sequence occurring in the third and fourth domains. Two
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the unique chemical structures, calmodulin, S100a and S100S, has enabled
researchers to begin study of structure-function relationships in these
proteins.
Calmodulin
of these substi tuti ons are changes in the ami dati on state of Asn-97 and Gl n-
135. In addition, the Renilla protein has a deletion of the glutamine at posi­
tion 3 (44).
The amino acid sequence of calmodulin from the protozoan Tetrahymena
pyriformis (46) has thirteen differences from the vertebrate protein. The
majority of these are in the third and fourth domains, as in the invertebrate
cal modul in, and the threoni ne at posi ti on 146 has apparently been del eted. In
addition, three amino acid sUbstitutions occur in the second domain: the
amidation state of asparagine-60, a threonine to serine substitution at posi­
ti on 70, and a methi oni ne to 1 euci ne substi tuti on at posi ti on 71. El even of
the thirteen amino acid substitutions can be accounted for by single
nucleotide changes in the codon structure.
Calmodulin from spinach leaves has twelve amino acid substitutions from
the vertebrate sequence (47-49). Again, most of these are in the third and
fourth doma ins of the mol ecul e, wi th several notable excepti ons. The gl yci ne
at position 96 of vertebrate calmodulin is replaced by a glutamine in the
spinach sequence. This substitution is only compatible with a minimum two
nucl eoti de change in the DNA sequence of the gene for cal modul in. More impor­
tantly, glutamine at position 96 occurs between the Y and Z vertices of the
model EF hand calcium binding loop of domain two (12-13,47-48). It is not
clear how this substitution affects the binding of calcium. Spinach cal­
modulin also contains a single cysteine residue at position 26 (45), which
corresponds to the -Y vertex of the model EF hand of domain one. The func­
tional significance of this substitution is not known, since detailed calcium
bi ndi ng studi es of the spi nach protei n have not been reported. The cystei ne
as well as the other ami no aci d substi tuti ons suggest that pl ant cal modul ins
may have functi onally si gni fi cant ami no aci d sequence di fferences from ver-
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tebrate calmodulin.
Recently, the partial amino acid sequences of two novel calmodul ins have
been determined (50). These sequences are shown in Figure 2. Calmodulins
from the green alga Chlamydomonas reinhardtii (50) and the slime mold Dic­
tyostel i urn di scoi deum (51) do not contai nNE-trimethyllysi ne and have lysi ne
at posi ti on 115. Thi s difference coul d be due to the absence of the methyl a­
tion enzymes. Alternatively, other amino acid substitutions in this region
of Chlamydomonas calmodulin may affect the susceptibility of lysine 115 to
methylation. Notably, the threonine at position 117 and the aspartic acid at
position 118 are replaced by serine and glutamic acid. These substitutions
make the region at positions 117-120 of Chlamydomonas calmodulin homologous
to residues 81-84 in the third domain of vertebrate calmodulin. This region
has been impl i cated in the i nteracti on of vertebrate cal modul in wi th troponi n
I (37 ,52). The appearance of an identical sequence in the fourth domain of
Chlamydomonas calmodulin raises the possibility that the protein may have
significant functional properties that are different from vertebrate cal­
modulin. Amino acid sequence studies of calmodulin from Dictyostelium
discoidium indicate that the slime mold protein is similar to other cal­
modulins, but does not contain N E-trimethyllysine. In addition, Dic­
tyostelium calmodulin contains serine at position 111, asparagine at posi­
tion 118, and leucine at position 130. All three of these differences from the
bovine brain protein are compatible with single nucleotide changes in the
codon structures. The ami no aci d sequence determi nati on of the Di ctyoste1 i urn
protein is shown in the Appendix.
A number of i nvesti gators have i dentifi ed cal modu1 i n-1 ike protei ns in
Chlamydomonas flage11ae (53), barley (54), and mushrooms {55}. However,
since calmodulin is a member of a family of structurally and functionally
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related calcium binding proteins, it is reasonable that calmodulin-like
proteins exist in these tissues. Troponin C could be considered a tissue
speci fi c , cal modu1 i n-1 ike protei n , but troponi n C has a well defi ned functi on
in striated muscle (3). The biochemical characterization of calmodulin-like
proteins by amino acid sequence analysis and functional properties should
clarify the relationships among four-domain calcium modulated proteins.
Calmodulin has no known enzymatic activity but has been shown to
stimul ate numerous enzymes in vi tro ina cal ci urn dependent manner (37). These
include: 1) enzymes of cyclic nucleotide metabolism (56-62),2) various AT­
Pases (63-67), 3) NAD kinases in plants (68) and invertebrates (69), 4)
protein kinases (18-19,70-72), and a protein phosphatase (73). In some
cases, these in vitro effector activities of calmodulin may reflect true
physi 01 ogi cal functi ons. The holoenzyme of musc1 e phosphoryl ase kinase has
been puri fi ed to chemi cal and enzymati c homogenei ty and has been found to con­
sist of four subunits, a, i3, y, and <5 (18,43). The <5 subunit was shown to be the
calcium sensitizing component and to be identical to vertebrate calmodulin
(18). According to similar criteria (16-17), myosin light chain kinase
holoenzyme also contains calmodulin as an integral subunit.
The abi1 ity to demonstrate a calcium and ca1modu1 in stimu1 ation in vitro
does not necessarily reflect a physiological function of calmodulin. In
reconstituted actomyosin ATPase assays, calmodulin quantitatively sub­
stitutes for troponin C, the physiological calcium sensitizing factor of
skeletal muscle actomyosin ATPase (74-75). It is possible that calmodulin
cou1 d substi tute for endogenous cal ci urn dependent regu1 ators in some of the
other in vitro activities attributed to calmodulin.
Calmodulin stimulation of the enzymes of cyclic nucleotide metabolism
has been an intriguing and controversial aspect of calmodulin function.
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Several forms of cycl i c nucl eoti de phosphodi esterase acti vi ty can be
separated by i on exchange chromatography (76). One of these has a rel ati vely
low KM for cAMP, can also utilize cGMP as substrate, and shows ten fold ac­
ti vati on wi th cal ci urn and cal modul in (76-77). Cheung (56) detected a protei n
acti vator of cycl i c nucl eoti de phosphodi esterase, and Kak i uchi and Yamazak i
(57) observed a cal ci urn dependent stimul ati on of phosphodi esterase. Teo and
Wang (78) 1 ater showed that the activator was a calcium binding protein. Wat­
terson et al. (36) demonstrated that chemi cally homogeneous troponi n C-l ike
protein (calmodulin) from bovine brain could activate the enzyme in vitro.
Kl ee (77) purifi ed the porci ne brai n acti vator protei n and showed that it was
identical to calmodulin. However, the calmodulin stimulated phos-
phodiesterase accounts for only a fraction of the total cyclic nucleotide
phosphodiesterase activity in brain extracts (76-77). Thus, the
physiological role of calmodulin activation of phosphodiesterase remains un­
clear for brain and other tissues.
A similar situation exists for calmodulin stimulation of brain
adenyl ate cyclase. The adenyl ate cyclase activity in brain membrane frac­
tions can be stimulated about four fold by calmodulin and calcium (58-59).
Storm and his colleagues (60) initially reported that the guanyl nucleotide
regulatory subunit was required for calmodulin activation of adenyl ate cy­
clase. Recently, Salter et al. (61) have demonstrated that calmodulin ac­
tivates the isolated catalytic subunit of the enzyme after gel filtration in
the presence of ammoni urn sul fate. Recent work wi th forskol in and manganese
ion activation of adenyl ate cyclase indicates that the state of the catalytic
subunit may indeed be modulated by other factors in addition to the guanyl
nucleotide regulatory subunit (79).
Adenyl ate cyclase from Bordetella pertussis can be activated by cal­
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modulin in acalciumdependentmanner (80). This observation is particularly
; ntri gui ng because the Bordetell a enzyme is extracell u1 ar (80), un1 ; ke most
mammalian cyclases which are intracellular, plasma membrane-associated
proteins (61,79). In addition, Bordetella synthesizes a protein toxin which
catalyzes the ADP-ribosylation of the inhibitory guany1 nucleotide
regu1 atory protei n in pancreati c i sl et (81) and neurob 1 astoma-g1 i oma hybri d
cell (82) adenylate cyclase systems.
The guanylate cyclase from the protozoan Tetrahymena pyriformis is
stimulated only by Tetrahymena calmodulin, and not by vertebrate or inver­
tebrate calmodulins (83). However, Tetrahymena calmodulin activates ver­
tebrate phosphodiesterases (83-84), adeny1ate cyclase, myosin light chain
kinase, and (Ca 2+_Mg 2+) ATPase (85) as well as plant NAD kinase (85).
Several of the ami no aci d sequence di fferences between Tetrahymena and ver­
tebrate calmodulin occur in the fourth domain (46). These changes include a
histidine residue substituted for the glutamine at position 135 of the ver­
tebrate protein, an arginine at position 143, and a deletion of the threonine
at position 146. These substitutions in the fourth domain alter the reac­
tivity of the protein to the site specific antiserum developed by Van E1dik
and Watterson (86). However, it is not known how these ami no aci d substi tu­
tions in Tetrahymena calmodulin alter the specificity for activation of the
guanylate cyclase.
In addition to calcium dependent activation of enzymes, calmodulin
disp1 ays calcium dependent binding to troponin I (74), spectrin (87), cal des­
mon (88), fodrin (89), and a microvi11 us protein (90), and calcium indepen.­
dent binding to gap junction (13), histones (91-92), and myel in basic protein
(91,93). In order to eva1 uate the physi 01 ogi cal re1 evance of these i nterac-
ti ons, it is important to exami ne the 1 imi tati ons of the methods used to i den-
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tify cal modul in bi ndi ng protei ns. Three methods have generally been used to
demonstrate calmodulin binding to proteins (13,48,94-95). First, proteins
are shown to bind to calmodulin-Sepharose conjugates in the presence of cal­
cium and to elute with buffers containing a calcium chelator (48). Studies of
thi s type are 1 imited by the amount of active calmodul in which has been cova­
lently coupled to the Sepharose. Experiments using calmodulin-Sepharose
conjugates must also use buffers which are relatively isotonic. Some
proteins, such as the tau protein of microtubules, bind to calmodulin­
Sepharose when appl i ed in hypotoni c buffers (96). Such an i nteracti on is not
suffi ci ent to estab1 i sh that tau is the target for cal modul in in the regul a­
tion of microtubule depolymerization in vitro (48,96). Second, calmodulin
binding proteins are identified by the binding of radioiodinated calmodul in
to proteins which have been separated by electrophoresis in polyacrylamide
gel s (90,97 -98). An important consi derati on in thi s method is the procedure
for the renaturation of the proteins in the gel matrix following elec­
trophores is. Thi rd, cross 1 ink i ng of ca 1 modul into a bound protei n or peptide
has been used to demonstrate an interaction (99). For example, Giedroc et al.
(99) found stoichiometrically cross-l inked species of calmodul in and endor­
phin peptides using bis(sulfosuccinimidyl) suberate.
Calmodulin appears to interact with various supramolecular structures
and cellular organelles (89,97-98,100-102). Calmodulin binding proteins
have been examined in subcellular fractions of chicken embryo fibroblasts
(100). While 77-93% of the calmodulin was present in the soluble fraction, a
small but reproduci bl e amount of calmodul in was found in the nucl ear"
mi tochondri al /lysosomal, and mi crosomal fracti ons (100). These parti cul ate
fractions also contained a number of calmodulin binding proteins as deter­
mi ned by a gel overl ay method (98,100). These resul ts suggest that some of the
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targets of cal modul in acti on may resi de on vari ous subcell ul ar organell es or
structures, and that calmodul in bi ndi ng protei ns are not 1 imi ted to sol ubl e
enzymes.
Siekevitz and colleagues (89,101) have demonstrated that calmodulin is
present in a preparation of postsynaptic densities from canine cerebral cor­
tex. These supramolecular complexes also contain fodrin, an actin-binding
protein which also binds iodinated calmodulin in a gel overlay procedure
(89,97). Immunocytochemical localization of calmodulin at the level of the
el ectron mi croscope al so i ndi cates that postsynapti c densi ti es contai n cal­
modulin (102).
S100
S100 refers to a heterogeneous fracti on of low mol ecul ar wei ght, aci di c
proteins which bind calcium. In 1965, Moore and McGregor (103) identified
S100 as prominent in soluble extracts of rat brain, but not apparent in ex­
tracts of rat 1 i ver. Moore (104) developed a procedure to i sol ate thi s frac­
tion, called S100 to signify its partial solubility in saturated ammonium
sulfate at neutral pH. Since that first report, a number of methods for the
isolation of S100 from bovine brain have been described (105-111). These in­
volve routine techniques of protein chemistry such as salt fractionation,
col umn chromatography, and, in some cases, preparati ve gel el ectrophoresi s ,
Isobe and co-workers (33-34,112) have purified two polypeptides, S100a and
S100�, by more extensive use of these procedures. During the course of the
studi e? presented in thi s thesi s , we have demonstrated (113) the puri fi cati on
of polypepti des of the S100 fracti on by the combi ned use of sal t fracti ona­
ti on, i on exchange chromatography, affi ni ty-based adsorpti on chromatography
on phenothiazine-Sepharose conjugates, and reverse phase high performance
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liquid chromatography. Hidaka and colleagues (114) have recently described
the purifi cati on of one of the S100 components usi ng affi ni ty-based
chromatography on immobilized naphthalene sulfonamide derivatives.
During the last several years, purified S100a and S100S have become
avail abl e. Most of the earl i er studi es of S100 have uti 1 i zed or moni tored a
heterogeneous mixture of proteins (105-110). As a result, a large body of
confusi ng 1 i terature has evol ved. Three gui del i nes are useful in the eva1 ua­
tion of this literature. First, S100 is a protein fraction and the relative
amounts of S100a and S100a have not been determi ned. Vari ab 1 e amounts of ca1-
modu1 in and ca1modu1 in fragments are a1 so present in some S100 preparations
(36,112,115-116). Second, since there is no known function for ca1modu1in­
dep1 eted S100, its protei n components shou1 d not be consi dered subuni ts of an
enzymatic, structural or regulatory complex. Isobe et a1. (117) have
presented evidence that in solution S100a and S100a exist as dimers of the
form a1 a1 (S100a) and 82 (S100b), but the si gni fi cance of thi s dimeri zati on
is not clear. Third, S100 is usually monitored by immunoreactivity with
heterologous antisera prepared against a heterogeneous protein mixture.
Thus, most anti sera di rected agai nst S100 do not defi ne a si ng1 e structure.
In thi s thesi s we have addressed thi s prob1 em through immunochemi cal studi es
of purified polypeptides.
S100a (33) and S100a (34) are po1ypepti des of 93 and 91 ami no aci ds, res­
pectively, which share 54 identical amino acids. The amino acid sequences of
S100a and S100a are shown in Fi gure 3. Of the 39 sequence di fferences between
S100a and S100a, 23 are compatible with single nucleotide substitutions, and
S100a conta ins a tryptophan res i due whi ch is 1 ack i ng in S100a. Both S100a and
S100a contai n the sequence requi rements for the formati on of a EF hand cal ci urn
binding structure. In addition, residues 20-32 in both S100 proteins share
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amino acid sequence homology with the amino terminal calcium binding struc­
ture in the bovi ne vi tami n 0 dependent cal ci urn bi ndi ng protei n (30). Szebenyi
and Moffat (30) have suggested that the 5100 protei ns contai n cal ci urn bi ndi ng
sites in this region, although crystallographic data are necessary to
estab1 ish these si tes. Crystal s sui tab1 e for di ffracti on studi es have been
reported for S100S (39), but electron density maps are not yet available.
The physicochemical properties of 5100 are also subject to reevalua­
tion. Ca1issano et a1. (118) examined the calcium binding properties of 5100
using changes in tryptophan fluorescence and equilibrium dialysis. Only
S100a contai ns tryptophan (33), however, a1 though S100S may di sp1 ay
anomalous tyrosine fluorescence (119). In addition, the affinity of 5100 for
cal ci urn may vary wi th the state of the su1 fhydry1 s (120). Thus, three proper­
ti es of 5100 are important to our understandi ng of the protei ns: the nati ve
oxidation states of the su1fhydry1s, the affinities and stoichiometries of
calcium binding, and the nature of the ultraviolet absorption spectra.
The functi on of the 5100 protei ns is not known, but several in vi tro ac­
tivities have been described (113-114,121-124). Apparent calcium dependent
activities include interaction with synaptosomal (121) and artificial (122)
membranes, binding to immobilized phenothiazines (113) and naphthalenes
(114), stimulation of nucleolar RNA polymerase activity (123) and
depolymerization of tubu1in (124). The only activities which have been ex­
amined using purified polypeptides are the interactions with drugs (113-114)
and the depo1ymerization of tubulin (124).
Until recently, 5100 has been considered a nervous system-specific
protei n anti gen (125-126) , whi ch is primari ly local i zed to gl i al cell sin the
central nervous system and to Schwann cell sin the peri phery. Hi daka et a1 .
(127) have i sol ated S100S from bovi ne abdomi nal adi pose ti ssue, and Kanamori
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et al. (128) have found immunoreactive S100 in human T lymphocytes. These
fi ndi ngs i ndi cate that S100 is not speci fi c to the nervous system and suggest
that the tissue distribution of S100a and S100S should be examined with
specific antisera.
The pharmacology of calcium modulated effector proteins is still in its
infancy. Honda et al • (129) reported that the acti vati on of cycl i c nucl eoti de
phosphodi esterase by cal ci urn and an uni dentifi ed protei n coul d be i nhi bi ted
by chl orpromazi ne. Levi n and Wei ss (130) found that a number of phenothi azi ne
derivatives bind to calmodul in in a calcium dependent manner and block the ac­
tivation of phosphodiesterase (131). Since these initial reports,
phenothiazine derivatives have been shown to block calmodulin stimulated en­
zymes in vi tro when the cal modul i n- drug complex is formed pri or to i ncubati on
with the enzyme (37). However, phenothiazine drugs cannot dissociate the
phosphorylase kinase <) subunit from the holoenzyme (132). The exact nature of
the drug interaction with calmodulin in the absence and presence of various
enzymes has not been determined.
Phenothiazines are heterocyclic compounds that are used phar­
macologically as antipsychotics, antiemetics and tranquilizers (133). The
structures of three phenothiazine derivatives which have been used in our
studies are shown in Figure 4. Levin and Weiss (134) reported that the af­
finity of calmodul in for various phenothiazines and other neuroleptic drugs
correl ated wi th thei r potency as neurol epti c agents. However, the affi ni ty
of all classes of neuroleptic drugs for calmodulin does not correlate with
pharmacological potency (135-136). For example, the optical isomers of
butaclamol have similar affinities for calmodulin, but the + isomer is much
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more potent cl i ni cally than the - isomer (137). Thus, the i nvol vement of cal­
moduli n in the mechani sm of neurol epti c drug acti on has not been establ i shed
by pharmacological correlations.
Phenothi azi ne drugs and dyes have been used for many years to study the
active sites of enzymes (138), structural domains of albumins (139), and
structures on neurotransmitter receptors (140). Phenothiazines also in­
teract wi th membranes (141), induce shape changes in erythrocytes (142), and
intercalate into DNA (153-144). Phenothiazine ligands have been useful in
demonstrating structurally homologous nucleotide binding domains in dehy­
drogenases (145). Phenothi azi ne dyes, such as methyl ene blue, have been used
to probe the active sites of enzymes through dye-sensitized photooxidation
(138). Serum albumins have separate sites for various anion and cationic
drugs and dyes, including phenothiazines (139,146). Phenothiazines block
dopami ne receptor agoni st bi ndi ng in membrane preparati ons from neural ti s­
sue (140,147-148), and dopami ne receptor blockade has been invoked (147) to
explain the antipsychotic actions of phenothiazines. The phenothiazines can
al so produce tardive dyskinesias as the major side effect of chronic or, in
some cases, acute doses of drugs (149). Thus, the physiological and phar­
macol ogi cal rol e of phenothi azi ne drugs is an important questi on in cl i ni cal
pharmacology and psychi atry (147). The answer, however, i ncl udes many poten­
tial targets of action.
Regardl ess of the pharmacol ogi cal rel evance of the i nteracti on between
calmodulin and phenothiazines, these drugs have been used as inhibitors of
calmodulin stimulated enzymes (37) and as affinity ligands for calmodulin
puri fi cat; on (150-151). Phenothi azi nes have al so been used in cell systems
where calmodulin and calcium were thought to mediate a physiological event.
In several studies (152-162), inhibition of a process by a phenothiazine drug
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has been used as evidence for a calmodul in-specific process. Affinity based
chromatography on immobil i zed phenothi azi nes has been used as the fi nal step
in calmodulin purification (150-151). However, other purified calcium­
modul ated protei ns were shown to interact wi th immobil i zed phenothi azi nes in
a calcium dependent manner (113). In addition, Moore and Dedman (163) have
observed that vari ous uni denti fi ed protei ns from crude ti ssue extracts bi nd
to phenothiazine-Sepharose conjugates. Phenothiazines al so block the 1 ipid
activation of a protein kinase which does not require calmodul in (164). These
data indicate that phenothiazine drugs are not calmodulin-specific in­
hibitors. When our studies were initiated, the binding of trifluoperazine
and other phenothiazines to calmodulin (130) was assumed to be responsible
for the i nhi bi ti on of cal modul in stimul ated enzymes. However, the rel ati on­
ship between binding activity and inhibitory activity of the drugs was not
established.
The cal ci urn dependent bi ndi ng of phenothi azi nes to calmodul in remai ns a
useful tool to probe the structural and functional domains of the protein.
Storm and colleagues (165) have observed that the hydrophobic probe 1-
anilinonaphthalene-8-sulfonate binds to calmodulin in a calcium dependent
manner. Stei ner and Sternberg (166) found that the bi ndi ng of the fl uorescent
probe changes when calmodulin is part of the phosphorylase kinase complex. A
vari ety of 1 oca 1 anestheti cs i ncl udi ng mepacri ne (167) and adrenergi c drugs
including propranolol (167) and phenoxybenzamine (168) interact with cal­
modul in. Hi daka and coll eagues (169-172) have demonstrated that naphthal ene
sulfonamide derivatives block calmodulin activation of several enzymes.
These drugs are smooth muscl e rel axants, and can be used as affi ni ty 1 i gands
for cal modul in and S10013 puri fi cati on (114). The method of coupl i ng of the
drug to the sol i d support may affect the speci fi ci ty of the i nteracti on wi th
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calmodulin and S100S (114).
Summary
Calmodulin is a member of a class of structurally and functionally
related proteins. Calmodulin is widely distributed among eukaryotes, and the
amino acid sequence of calmodulin is highly conserved. The protein contains
multiple structural domains and has multiple activities in vitro, including
calcium dependent drug binding. In the studies presented in this thesis, we
have used phenothi azi nes as tool s to probe the rel ati onshi ps between struc­
tural domains and functional domains in calmodulin.
The approach to the problem of structure-functi on rel ati onshi ps can be
framed in three questions:
Do other cal ci urn modul ated protei ns show cal ci urn dependent drug bi ndi ng
activity?
What are the structural requirements for drug binding in calmodulin?
How is the drug binding activity of calmodulin related to its enzyme ac­
tivator and protein binding activities?
In these questi ons 1 i es the essence of our approach to the mol ecul ar as­
pects of the rel ati onshi p between the i nhi bi tory drug bi ndi ng aci ti vi ti es and
the functional activities of calmodulin. While other investigators (134-
137) have studied the inhibitory actions of many classes of drugs on cal­
modulin, we have examined the properties of the protein and structurally




Preparation of Calcium Modulated Proteins from Bovine Brain
homogenized in a Waring blender with three bursts of 30 seconds each in three
Calmodulin, S100a, and S100S were isolated from bovine brains using a
modification (113) of a procedure for the isolation of spinach calmodulin
(176). Mature bovine brains (PelFreez) were thawed at 4 °c and stripped of
meninges and accompanying blood vessels. All of the following procedures
were done at 4 °c unless otherwise indicated. The brains (1-2 kg) were
volumes (1 l/kg) of buffer H (50 mM Tris-HC1, pH 7.5,1 mM EGTA, 1 mM 2-mercap-
toethanol ). A homogenate supernatant (Sl ) was collected after centri fuga­
tion at 10,000 x g for one hour and filtering the supernatant through two
1 ayers of cheesecloth. The homogenate supernatant was brought to 60% satura­
ti on by the addi ti on of sol i d ammoni urn sul fate whi 1 e sti rri ng. The mi xture
was a 11 owed to sti r for one hour and was centri fuged at 10,000 x g for one hour.
The supernatant (S2 ) was collected by filtering through two layers of
cheesecloth and brought to pH 4.0 by the addi ti on of 50% H2 S04. The mi xture
was stirred for 1.5 hours and centrifuged at 10,000 x g for one hour. The
supernatant (S3 ) was decanted, and the pe1l et (P3 ) was redi ssol ved in water
wi th a few drops of 1 M Tri zma (Si gma) to pH -7.5. Thi s sol uti on was di alyzed
against two changes of 20 liters of water over 4 hours and then overnight
aga i nst 4 1 i ters buffer B (10 mM Tri s-HCl , pH 7.5, 1 mM EGTA, 1 rnM 2-rnercap-
toethanol, 0.2 M NaCl). Following dialysis, the redissolved P3 was cen­
trifuged at 50,000 xg for 1 hour, and the supernatant was appl ied to a col urnn
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(4.0 x 15.0 cm) of diethylaminoethyl-Sephadex A-50 which was equilibrated in
buffer B. The non-adsorbed material was el uted with 1 1 iter buffer B at 1-1.5
ml/min. The remaining material was eluted with a linear salt gradient using 1
1 iter buffer B (0.2 M NaCl) and 1 1 iter buffer B wi th 0.5 Madded NaCl (0.7 M
NaCl , fi nal ) as the 1 imi ti ng sol uti ons. Fracti ons of 10 ml were coll ected and
analyzed by polyacrylamide gel electrophoresis. Fractions containing
mater; al that comi grated in el ectrophores is wi th cal modul in or S100 standard
were pooled separately and dialyzed against two changes of 4 liters water
overni ght and for 4 hours agai nst 4 1 i ters buffer F (10 mM Tri s-HCl , pH 8.0, 1
mM 2-mercaptoethanol , 1 mM MgC12 ' 2 mM CaC12 ). The di alyzed materi al was ap­
pl i ed to a col umn (2.0 x 14 cm) of phenothi azi ne- Sepharose 4B equi 1 i brated in
buffer F at room temperature. Non-adsorbed materi al was el uted with 100 ml
buffer F and 240 ml of buffer F containing 0.4 M NaCl. Calmodulin or S100
protein was eluted with 80 ml of buffer E (10 mM Tris-HC1, pH 8.0,2 mM EGTA, 1
mM MgC12 ' 1 mM 2-mercaptoethanol , 0.4 M NaCl ). The col umn effl uent was col­
lected in fractions of 6 ml, and these fractions were analyzed by elec­
trophoresi s on polyacryl ami de gel s and by measuri ng the opti cal absorbance at
235 nm. The fractions containing absorbing material were pooled, dialyzed
overni ght agai nst at 1 east three changes of 100 vol urnes of water, and then
1yophi 1 i zed. The lyophi 1 i zed materi a1 whi ch had been el uted wi th buffer E was
redi ssol ved in water wi th a few mi crol i ters of 1 N NaOH to adj ust the pH to 7 .
Proteins were purified to apparent homogeneity by high performance liquid
chromatography at 30°C on a Waters �Bondapak Phenyl column (0.78 x 30 cm)
using a modification of the procedure reported by Klee et ale (177). Solvent A
consisted of 10 mM potassium phosphate, pH 6.1,0.5 mM EGTA and solvent B was
acetoni tri 1 e. Two ml of materi al were app1 i ed to the col umn whi ch had been e­
quilibrated in 20% B. Calmodulin eluted by changing the solvent composition
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The absorpti on spectra of protei n samp1 es were measured usi ng a Hew1 ett­
Packard 8450 u1 travi 01 et-vi si b1 e spectrophotometer. Samp1 es were di ssol ved
in 0.1 M ammonium bicarbonate and measured in 1 cm quartz cuvettes.
to 28% B, S100a el uted wi th 32%B, and S100S el uted wi th 36% B. In experiments
wi th di fferent col umns, the sol vent compos i ti on for e 1 uti on vari ed s 1 i ght1 y ,
but the relative elution of proteins was identical on all columns tested.
Pool s of materi al el uted from the col umn were coll ected, rotary evaporated to
remove the acetonitrile, dialyzed exhaustively against 10 mM ammonium bicar­
bonate and water, and 1 yophi 1 i zed. The 1 yophi 1 i zed protei n was stored at -20
°C. The overall yiel d was 30-50 mg of ca1modu1 in and 10-20 mg each of S100a and
S100S from each kg (wet weight) of stripped bovine brain.
Absorption Spectra
Amino Acid Analysis
Samp1 es for ami no aci d ana1ysi s were rotary evaporated to dryness in 18 x
150 mm Pyrex i gni ti on tubes. To each tube was added 0.5-1. a m1 of 6 N HC1 (J. T .
Baker) and a small crystal of phenol to protect tyrosine. The tubes were
seal ed under vacuum and incubated 20-24 hours at 115°C. Foll owi ng i ncuba­
ti on, the sampl es were rotary evaporated and redi ssol ved in samp1 e di 1 uti on
buffer (Pierce) consisting of 0.2 N sodium citrate, pH 2.20 containing 2%
thi odi glycol and 0.1% phenol. Samp1 es were analyzed on a Ourrum 0500 or LKB
4400 instrument. Analyses of samples for N £-trimethyllysine were performed
using an isothermal program as described by Van Eldik et al. (173).
Samples to be analyzed for tryptophan were dried in 12 x 75 mm Pyrex
tubes, and 0.050 ml of 4 N methane sulfonic acid containing 0.2% 3-{2-
aminoethyl) indole (Pierce) was added to each tube. The tubes were sealed
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under vacuum and incubated for 22 hours at 115°C. Foll owi ng i ncubati on, each
sampl e was neutral i zed with 0.045 ml of 4 N sodi urn hydroxi de and di 1 uted wi th
0.105 ml of sample dilution buffer.
Polyacrylamide Gel Electrophoresis
Electrophoresis in polyacrylamide gels in the presence of sodium
dodecyl sul fate was performed using the di sconti nuous buffer system
descri bed by Laemml i (174). Gel s were ei ther 1 arge sl abs of 20 x 20 x 0.2 cm or
smaller slabs of 10 x 12.5 x 0.03 cm.
Polyacyl ami de gel el ectrophoresi sin the absence of detergent was per­
formed using the method described by Watterson et al • (36), in 1 arge sl abs or
tubes (7.5 x 0.5 cm).
Following electrophoresis, gels were stained with 0.1 % (w/v) Coomassie
brilliant blue in 50% methanol, 9% acetic acid, and destained in 5% methanol,
9% acetic acid.
Alkylation of Sulfhydryls
Bovine S100a and S100S were alkylated using 14C-iodoacetate (Amersham,
54 mCi/mmol). Lyophilized S100a (62.5 nmol) and S100S (53 nmol) were dis­
solved in 1.0ml of 6 M guanidine-HC1, 0.1 M Tris-HC1, pH 8.0,1 mM EOTA, 0.12 mM
OTT. Sampl es were incubated for 30 mi nutes at room temperature. Iodoacetate
( 14C_l abel ed) was added to a fi nal concentrati on of 5111M and the sampl es were
incubated for 2 hours at 35°C. The reacti ons were stopped by the addi ti on of
50 III of 20 mM OTT to each. The reacti on sol uti ons were di alyzed for 15 hours
at 4
°
against 4 1 iters of 100 mM ammonium bicarbonate and for 12 hours at 4 °c
against 4 liters of 10 mM ammonium bicarbonate in cellulose dialysis tubing
(Spectrum Laboratories) with 6000-8000 nominal molecular weight cutoff.
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Samples were lyophilized and redissolved in 1.0 ml of 5 mM ammonium bicar­
bonate.
Performic Acid Oxidation
Protei n was oxi di zed wi th performi c aci d accordi ng to procedures
described by Hirs (175). Formic acid (Eastman or Aldrich, reagent grade) was
mi xed wi th 30% hydrogen peroxi de at a rati 0 of 19: 1 (v /v). Thi s performi c aci d
reagent was incubated at room temperature for two hours and then chi 11 ed to 0
°c in an ice bath. Protei n samp1 es were di ssol ved in formi c aci d to 1-2 mg/ml
and chi 11 ed to 0 °c for 30 mi nutes. A 2-3 fo1 d excess by vol ume of ice col d per­
formi c aci d reagent was added to the protei n sol uti on and incubated on ice for
2.5 to 3 hours. The samp1 e was rotary evaporated to dryness, redi ssol ved in
water and lyophilized.
Digestion with Proteases
Protein samples were dissolved at 1-3 mg/m1 in 0.1 M ammonium bicar­
bonate containing 1 mt� EGTA. Trypsin (Worthington, TPCK treated) was dis­
solved in 1 mM Hel at 1 mg/ml. Trypsin solution was added to the protein
samples at 1:100 (w/w) ratio. After incubation for two hours at 37°C, a
second aliquot of trypsin solution was added. The final ratio of trypsin to
sample was 1:50 (w/w). Samples were covered tightly and incubated at 37°C
overni ght, usually 14-18 hours total. Foll owi ng the i ncubati on, samp1 es were
lyophilized and redissolved at N2 mg/m1 in water.
Trypti c pepti des of cal modul in, S100a and S100S were separated by hi gh
performance liquid chromatography on a Whatman ODS-3 column (0.94 x 25 cm)
usi ng a vari ati on of the methods descri bed by Watterson et a1 • (176). Sol vent
A was 0.01 N HC1 (U1 trex, J. T. Baker) and sol vent B was acetoni tri 1 e (Fi sher
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HPLC grade). A 1-2 m1 a1 i quot of the trypti c di gest (- 2 mg/m1 ) was app1 i ed to
the col umn which was equil ibrated in 95% A, 5% B. Non-absorbed material in­
cluding salts and amino acids were eluted by pumping at 5% B at 2m1/min, 30°C.
Pepti des were e1 uted wi th i ncreasi ng amounts of acetoni tri 1 e in the sol vent
mixture. The effluent was monitored for optical absorbance at 215 nm. Frac­
tions were collected either as 0.5 min/tube or as pool s of absorbance peaks,
rotary evaporated to dryness, redissolved in water, and lyophilized. The
pepti des were redi sso 1 ved in water and stored at -20°C or dri ed and stored at
-20°C.
Digestion of samples with mouse submaxillary gland protease
(Boehringer) was performed exactly as described for trypsin.
Cyanogen Bromide Digestion
Sampl es for cyanogen bromi de di gesti on were di ssol ved in 70% formi c aci d
at 5-10 mg/ml. Cyanogen bromide was added as a 0.64 g/ml solution in
acetoni tri 1 e to a 100-400 fol d mol ar excess of cyanogen bromi de over
methionyl residues. The samples were mixed, sealed, and incubated for 22
hours at room temperature. Following incubation, the samples were rotary
evaporated to dryness, redissolved in water, and lyophilized. The
lyophilized material was dissolved in water and stored at -20°C.
Citraconylation
Protein samples were dissolved at 1 mg/ml in water and adjusted to pH 8.5
with 10 N NaOH. Five aliquots of 100 III citraconic anhydride (Pierce) were
added at 10minute interval s while stirring the sample. The pH was maintained
at 7.5 - 8.5 by the addition of 10N NaOH. The total reaction time was 5
mi nutes. The sampl e was desal ted on a Sephadex G-25 col umn (2.0 x 30 cm) in 0.1
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M NH4 HC03• The eluant was collected in 3.5 ml fractions. The material which
el uted at the voi d vol ume of the col umn was cl ear to 1 i ght yell ow in color and
contai ned most of the ci traconyl ated protei n. Thi s materi al was 1 yophi 1 i zed
and redissolved in 1.0 ml O.lM NH4 HC03 ' 1 mM EGTA, and then digested with
tryspi n for four hours at 37°C. The reacti on was i nhi bi ted by the addi ti on of
a soybean trypsin inhibitor (Worthington) to a concentration equal to that of
the trypsin. This mixture was incubated for 30 minutes at 37°C, and
lyophilized. The digested sample was redissolved in 1 ml of 10% formic acid,
incubated four hours at 37°C, and rotary evaporated. Thi s materi al was di s­
sol ved in 1 ml of 50% aceti c aci d (J. T. Baker Photrex) and incubated overni ght
at 4°C. The solution was rotary evaporated and redissolved in 600 �l of
water. The pepti des were separated exactly as descri bed for trypti c pepti des
except an extra 10 minutes was allowed for the elution of non-adsorbed
material at 5%B.
Iodination of Proteins
Bovine brain calmodulin, S100a and S100S were iodinated for radioim­
munoassays using the procedure of Dorval et al. (182) as modified by Van Eldik
and Watterson (86). Bri efly, 5-10 �g of protei n in 0.15 M sodi urn phosphate, pH
7.5 was iodinated at 23°C for 25 seconds using 4 �g of Chl oramtne-T and 1 mCi
of Na 1251 (Amersham, 100mCi /ml , carri er free). For S100S the reacti on time
was extended to 5 mi nutes. The reacti on mi xture was immedi ately transferred
to a column (lx15 cm) of Sephadex G-10 (Pharmacia) equilibrated in 0�15 M
sodium phosphate pH 7.5. Al iquots of iodinated protein were stored at -20°C.
A sample of the iodinated protein was routinely subjected to electrophoresis
on polyacy1amide gels in the presence of sodium dodecyl sulfate.
Autoradiograms of these gels showed that the iodinated protein comigrated
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with unlabeled protein. Bovine brain and chicken gizzard calmodulin were
i odi nated accordi ng to the method of Ri chman and Kl ee (180) or as modi fi ed by
Marshak et al. (113) for use in phenothiazine-Sepharose binding assays and
gel overlayproedures (98). Calmodulin (511g) was incubated at room tempera-
ture in a mixture containing 0.3 llg lactoperoxidase (Ca1biochem), hydrogen
peroxide (final dilution, 1:5000 of 30%, v/v), 1 mCi Na 1251 (Amersham, 100
mCi/m1, carrier free), 0.4 mM CaC12 ' and 0.15 M sodium phosphate, pH 7.5.
Foll owi ng i ncubati on for 14 mi nutes, the free Na 1251 was removed by gel fi 1-
tration on a column (1 x 15 cm) of Sephadex G-10 equilibrated in 50 mM Tris-
HCl, pH 7.4. The iodinated protein was collected, stored, and monitored as
described above.
Production of Antisera
Anti sera were produced in New Zeal and whi te femal e rabbi ts usi ng
procedures described by Van Eldik and Watterson (86). Performic acid-ox­
idized S100a and SlOOS were injected according to the following protocol: 0.4
mg in compl ete Freund's adjuvant (Ditco) on day 1 foll owed by 0.1 mg in i ncom­
plete Freund's adjuvant (Difco) on days 7, 9,13,15, and 17. The first serum
was obtai ned from blood coll ected on day 27. Thereafter, rabbi ts were gi ven
booster injections of 0.1 mg antigen in incomplete Freund's adjuvant every
two weeks. After several weeks, booster injections were given every 4-6 weeks
as recommended by Van El di k and Watterson (86). Unoxi di zed S100S was i nj ected
according to a similar protocol, but the initial injection contained 1 mg of
protei n anti gen, and the booster i nj ecti ons contai ned 0.5 mg of S100S per rab­
bit.
Peptide ME13B was synthesized as described below, removed from the sup­
port usi ng hydrogen fl uori de (183), and puriti ed by reverse phase hi gh per-
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formance 1 i qui d chromatography. The compos i ti on of the pepti de was veri fi ed
by amino acid analysis. The peptide was crosslinked to chicken ovalbumin
using gl utara1 dehyde according to the procedure of Audibert et al . (184). The
pepti de (1430 nmo1 ) was di ssol ved in 2.71 m1 of 0.1 M sodi urn bi carbonate, and
2.44 mg of chicken ovalbumin in 0.5 m1 of 0.1 M sodium bicarbonate was added.
Thi s mi xture contai ned a 1.2 fol d mol ar excess of free ami no groups on the pep­
ti de over the carri er protei n. The sol uti on was sti rred for 60 mi nutes at room
temperature, and 0.017 ml of 2.5% glutaraldehyde (v/v) was added. Following
i ncubati on at room temperature for 45 mi nutes in the dark, another a1 i quot of
0.017 m1 2.5% gl utara1 dehyde was added to give a final gl utara1 dehyde concen­
tration of 2.63mM, and the solution was allowed to stir in the dark for an ad­
ditional five hours. The mixture was dialyzed at 4 °c against three changes of
100 m1 of 0.1 M ammoni urn bi carbonate for one hour each. The di a1ysate was col­
lected, 1yophi1yzed, and hydrolyzed in vacuo in 6 N HCl for 24 hours. Amino
aci d analysi s showed that 1 ess than 2% of the ME13B pepti de was found in the
pooled dialysate. The peptide-ovalbumin solution was further dialyzed for
6.5 hours at 4 °c against two liters of 0.01 M sodium phosphate, pH 7.2,0.15 M
sodium chloride. The conjugate was stored in aliquots at -80°C.
For injection, an aliquot of the ME13B-ova1bumin conjugate (100 nmol
pepti de) was ernul sif; ed in 1.0 m1 of comp1 ete or i ncomp1 ete Freunds adjuvant.
The injection protocol was the same as decribed above.
Radioimmunoassays
Radi oimmunoassays were performed as descri bed by Van El di k and Watter­
son (86). Oi rect radi oimmunoassays were performed in RIA buffer (0.1 M NaCl ,
0.001 M EOTA, 0.02 M Tris-HC1, pH 7.6) containing 0.2% (w/v) bovine serum a1-
bumi n. Reacti on mi xtures 0 f 0.10 m1 contained a fi xed amount of 1251 - 1 abel ed
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protein (50,000 cpm; 1 ng), various concentrations of antisera, and enough
normal rabbit serum (Cappel Laboratories) to give a final serum volume of 5 to
10 lJ 1 in each assay tube. Fol 1 owi ng overni ght i ncubati on at 4 °c, 50 u 1 of goat
anti-rabbit serum (Cappel Laboratories) were added, and the incubation was
conti nued at 4 °c for 6-10 hours. RIA buffer (0.5 ml ) was added, and the mi x­
ture was centri fuged at 900 x g for 10 mi nutes. The resu1 ti ng supernatant was
removed, and the radioactivity of the pellet was measured in a y radiation
spectrometer (Packard or Beckman).
Competi ti on radi oimmunoassays were performed as above us i ng an amount
of anti serum determi ned to gi ve preci pi tati on of 50% of the radi oacti vi ty, as
determi ned by di rect radi oimmunoassay. Vari ous concentrati ons of competi ng
anti gens were incubated wi th the anti sera overni ght at 4 °C. The i odi nated
antigen was then added (50,000 cpm; 1 ng) and the mixture was incubated over-
ni ght at 4 °C. Goat anti -rabbi t serum was then added, and the assay mi xtures
were incubated and processed as described above.
Peptide Synthesis
All the methods used for sol i d phase pepti de synthesi s are revi ewed by
Barany and Merrifield (182). Peptides were synthesized on p-methylbenzhy­
drylamine-resin (U.S. Biochemicals). The resin consisted of it divinylben­
zene cross-linked polystyrene beads (100-200 mesh) derivatized to 0.96 mM
nitrogen per gram. Boc-amino acids (Peninsula Laboratories) were coupled
either directly using dicyclohexylcarbodiimmide (Pierce) or as the symmetric
anhydride. Dichloromethane (Fisher) was distilled from sodium carbonate
prior to use.
Pepti des AE21, FF25, and AF20 were provi ded by K. Fok and B. Eri ckson ,
The Rockefeller University, New York.
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Equilibrium Binding of Chlorpromazine
The equilibrium for the binding of chlorpromazine by calmodulin was
measured using gel excl usion chromatography as described by Hummel and Oreyer
(178). Bi ndi ng experiments were performed in buffer H01 [50 mM Tri s-HCl , pH
7.4, 150 mM NaCl , 1 mM CaC12 ' and vari ous concentrati ons of 2-chl oro-10- (N, N­
dimethyl) 3-ami nopropyl phenothi azi ne (chl orpromazi ne), a gi ft of Or. Harry
Green, Smith Kline and French Laboratories]. Bovine brain calmodulin was
di ssol ved in buffer H01 at a concentrati on of 62.5 llM (1.04 mg/ml) as deter­
mi ned by ami no aci d analysi s , The concentrati on of chl orpromazi ne was deter­
mined by absorbance at 254 nm using c M=30,000 (179). The calmodul in sol ution
was allowed to equilibrate for at least 30 minutes at room temperature. An
a1 i quot (20-80 II 1 ) of the cal modul in sol uti on was app1 i ed to a col umn (0.5 x 30
cm) of Bio-Ge1 P6 (100-200 mesh, BioRad) which had been equilibrated
previ ously in buffer H01 contai ni ng the same concentrati on of chl orpromazi ne
as in the cal modul i n sol uti on. The col umn was e1 uted wi th buffer H01 at a flow
rate of 0.3 ml Imi n us i ng a Waters 6000A pump, and the absorbance of the ef­
fl uent was monitored at 254 nm using either a Waters 480 or 441 detector. Ab­
sorbance measurements were transmitted to a Hewlett Packard 1000 computer
using a Hewlett Packard analog/digital converter. The areas of peaks and
troughs in the chromatogram were integrated using Hewlett Packard 3356
Laboratory Automation System software.
Standard sol uti ons of chl orpromazi ne in buffer H01 for cal i brati on con­
tained 0.01 and 0.1 mM chlorpromazine above the concentration of ch10r­
promazi ne in the buffer. Concentrati ons of drug were determi ned spectrophot-
metrically as described above.
Internal cal ibration of the binding of chlorpromazine to calmodul in was
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performed as described by Hummel and Dreyer (178). An aliquot of the cal­
modul in sol uti on was di 1 uted wi th vari ous amounts of standard ch1 orpromazi ne
solutions to give the desired excess amount of drug. This solution was e­
qui 1 i brated for at 1 east 30 mi nutes at room temperature and fi 1 tered on the
BioGel P6 column as described above.
Binding experiments were performed exactly as described above using
buffer HD2 contai ni ng 50 mM Tri s-HCl pH 7.4, 150 mM NaC1 , 4 mM MgC12 ' 1 mM EGTA
and various concentrations of chlorpromazine.
Phenothiazine-Sepharose Preparation
Phenothi azine-Sepharose conjugates were prepared usi ng 2-ch1 oro-10-( 3
amino propyl) phenothiazine (a gift of Dr. Albert Manian, National In­
stitutes of Health) according to procedures described by Van E1dik et al.
(53). Cyanogen bromi de acti vated Sepharose 4B (Pharmaci a) was swell ed over­
ni ght in 1 mM HCl at 4 °c and washed at room temperature wi th 1 mM HCl , water,
and 0.2 M NaHC03 to pH -8. The phenothi azi ne deri vati ve was di ssol ved at 50
mg/m1 in 50% ethanol, pH 6. The drug sol uti on was added dropwi se to a sl urry of
activated Sepharose 4B (1:1, v/v in 0.2 M NaHC03 ) while stirring slowly at a
ratio of 100 mg drug/10 g dry Sepharose 4B. The reaction proceeded with
shaking for 2 hours at room temperature in a covered vessel. The resin was
washed as before, and 1 eft as a 1: 1 (v /v) sl urry in 0.2 M NaHC03 . To the sl urry
was added an equal vol ume of 0.5 M ethanol ami ne, and the mi xture was incubated
wi th agi tati on for 35 mi nutes at room temperature. The deri vati zed Sepharose
was washed as above and stored as a 1: 1 (v/v) sl urry in buffer E (10 mM Tri s­
HCl , pH 8.0, 1 mM 2-mercaptoethanol , 1 mM EGTA, 1 mM MgC12 ). The amount of 2-
ch10ro-10-(3-aminopropyl) phenothiazine coupled to the resin was estimated
spectrophotometri cally by measuri ng the di fference in opti cal absorbance at
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308 nm between settl ed res in and settl ed, unmodi fi ed Sepharose 4B. Assumi ng
an extinction coefficient of 4500 (179), the concentration of coupled
phenothiazine was 3 mM.
Phenothiazine-Sepharose Binding Assays
Bi ndi ng experiments usi ng phenothi azi ne-Sepharose conj ugates were per­
formed according to the procedure described by Marshak et al. (113). In
direct binding experiments, 4-18 ng of 125I-labeled chicken gizzard or bovine
bra inca 1 modul in ( 180) were incubated for 60 mi nutes at room temperature wi th
vari ous amounts of phenothi azi ne-Sepharose conj ugates and unmodi fi ed
Sepharose 4B. Each mi xture conta i ned 50 II 1 of packed res in, lOll 1 of i odi nated
cal modul in and 50ll 1 of buffer 1 (10 mM Tri s-HCl , pH 7 .4, 1 mM MgC12 ' 1 mM 2-
mercaptoethanol , 2 mM CaC12 ' 5 mg/ml bovi ne serum al bumi n). Foll owi ng i n­
cubation, the resin was washed once with 1.0 ml of buffer 1, three times with
1.0 ml each of buffer 2 (buffer 1 containing 0.2 M NaCl) and three times each
with buffer 3 (10 mM Tri s-HCl , pH 7.4, 1 mM MgC12 ' 1 mM 2-mercaptoethanol , 2 mM
EGTA, 0.2 M NaCl, 5 mg/ml bovine serum albumin). The washes with buffers 1 and
2 (unbound material) and buffer 3 (bound material) were pooled separately and
the amount of isotope was measured in a y radiation spectrometer (Packard
model 578 or Beckman Gamma 7000).
The design of competitive inhibition assays was similar to that used in
competi ti on radi oimmunoassays. Each assay mi xture contai ned 2.5 II 1 of packed
phenothiazine resin, 47.5 III of Sepharose 4B, 50 III of buffer 1, and lOlll of
unl abel ed protei n di 1 uted in buffer 1. The reacti on mi xtures were incubated
at room temperature for 60 minutes. Subsequent incubation with iodinated
calmodulin and buffer washes were done exactly as in binding experiments.
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Cyclic Nucleotide Phosphodiesterase Assays
Assays for cycl i c nucl eoti de phosphodi esterase were performed as
descri bed by Watterson et al. (181). Some assays were done us i ng buffer HD1
(see above) with 0.4 mM MnC12 ' at room temperature (22-24 DC) in order to
dupl i cate the condi ti ons used for equi 1 i bri urn drug bi ndi ng experiments. For
measurements of drug inhibition of phosphodiesterase activity, the ap­
propriate amount of drug was incubated for ten minutes at room temperature
wi th cal modul in. The cAMP substrate was added, and the reacti on was
initialized by the addition of the enzyme preparation. In all cases, the
amount of AMP produced was measured wi thi n the 1 i near range of i ncubati on time
and enzyme concentration (181).
Gel Overlay Experiments
Gel overl ay experiments were performed using the procedure described by
Carl in et al. (97) as modified by Burgess et ale (98). Following elec­
trophoresis, polyacrylamide gels were washed in 25% 2-propanol, 10% acetic
aci d to remove detergent. The protei ns were renatured in the gel matri x by
subsequent washes in overl ay buffer (50 mM Tri s-HCl , pH 7 .4, 0.15 M NaCl) and
overlay buffer containing 0.2% bovine serum albumin (Sigma). The gels were
then incubated overnight in overlay buffer containing 4 x 10 6 cpm of
radioiodinated calmodul in in the presence of 1 mM calcium chloride, 4 mM EDTA,
or 1 mM cal ci urn chl ori de and chl orpromazi ne. The unbound radi oacti vi ty was
removed with subsequent washes, and the gels were stained and destained as
described above. The dried gels were exposed to Cronex film (DuPont) at -80°C
using an intensifying screen.
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Other Materials
All chemi cal s were ACS reagent grade from Fi sher. Water was from a Darco
water sytem (Durham, North Carolina). Vitamin D-dependent calcium binding
protei ns were gi fts of S. Chri stakos, carp parval bumi n was a gi ft of R. Kret­
singer, and phosphorylase kinase was a gift of T. Chrisman. Myosin light
chain kinase, rabbit skeletal muscle troponin C, and subcellular fractions of
chicken embryo fibroblasts were provided by L. Van Eldik and W. Burgess.
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RESULTS
Isolation and Characterization of S100a and S100S
Calmodulin, S100a and S100S were isolated from bovine brains using a
combination of ammonium sulfate fractionation, anion exchange
chromatography, a ffi ni ty-based adsorpti on chromatography, and reverse phase
hi gh performance 1 i qui d chromatography. The i ni ti al homogeni zati on and am­
monium sulfate fractionation steps were based on procedures previously
described (36,176). Ani on exchange chromatography was performed on
diethylaminoethyl-Sephadex A-50 at pH 7.5 to obtain partial separation of
S100 and calmodul in as originally described by Watterson et ale (36). Figure
SA shows the Coomassie blue staining pattern of fractions from the ion ex­
change chromatographi c step whi ch have been separated by el ectrophoresi s on
polyacryl ami de gel sin the presence of sodi urn dodecyl sul fate. The separa­
ti on of S100 and cal modul in by i on exchange chromatography is hi ghly depen­
dent on pH. At pH 8.0 the S100 and calmodul in el ute together from the col umn,
whi 1 e at pH 7 .1, nei ther protei n is reta i ned in the presence of 0.2 M sodi urn
chloride. Subsequent chromatography of the S100 and calmodulin pools on
phenothiazine-Sepharose 4B removed high molecular weight contaminants as
shown in Fi gure 5B. Separati on of S100a and S100S was achi eved by chromatogr-
phy on llBondapak phenyl resin us i ng step e 1 uti ons wi th i ncreas i ng amounts of
acetoni tri 1 e in the mobi 1 e phase. Thi s procedure also separated cal modul in
from S100a and S100S. Fi gure 6 shows the chromatogram obtai ned when the ab­
sorbance of the effl uent from a preparati on of S100a and S100S is moni tored at
235 nm.
The ultraviolet absorption spectra of S100a and S100S are shown in
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Figure 7. Based on these spectra, S100a has a single residue of tryptophan
which produces the large absorbance maximum at 278 nm. S100S contains no
tryptophan, and shows a distinct phenylalanine fine spectrum with four rela­
tive absorbance maxima between 250 and 270 nm. The amino acid compositions of
S100a and S10013 are shown in Table 1. The pheny1a1anine:tyrosine ratio of 7:1
is consistent with the spectrum of S10013. The amino acid compositions of
S100a and S100� shown in Table 1 are indistinguishable from those calculated
from the amino acid sequences reported for S100a and S100S by Isobe and
Okuyama (33-34). It is not clear why s 1i ght1 y low val i ne val ues were observed
for both S100a and S10013 (Table 1). Isobe and Okuyama (33-34) a1 so obtained
low val ine val ues for hydro1ysates of S100a and SlOOp. Since S100a contains
no argi ni ne and SlOOp contai ns no tryptophan, these ami no aci ds cou1 d be used
to eva1 uate the separati on of S100a and S10013. In each case these val ues were
1 ess than 0.1 mol e of ami no aci d per mol e of protei n. S100a and S10013 were
alkylated using 14C-labe1ed iodoacetic acid in denaturing conditions. This
procedure 1 ed to the i ncorporati on of 0.37 mol es of 14C per mol e of S100a and
0.54 moles of 14C per mole of S10013. These values are consistent with the
relative amounts of cysteine in each protein.
In order to further characteri ze the S10013 i sol ated from bovi ne brai n,
the protei n was subj ected to di gesti ons wi th cyanogen bromi de or tryps in, and
the resulting peptides were isolated and characterized. Following alkyla­
ti on, S10013 was di gested wi th cyanogen bromi de, and the pepti de mi xture was
fractionated by reverse phase high performance liquid chromatography. The
separation of cyanogen bromide peptides of a1ky1ated SlOOp is shown in Figure
8A. Four fracti ons of the eff1 uent were coll ected correspondi ng to peaks of
absorbance at 215 nm and were found to conta in pepti des. The ami no aci d com­
pos i ti ons and recoveri es of these pepti des, shown in Table 2, account for the
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entire S100S molecule. Equal amounts (5.5 nmols) of radioactivity were
recoverd in two of the peptides, corresponding to peptides 58-74 and 80-91,
each of which contains a single residue of cysteine (34).
Tryptic digests of S100S and performic acid oxidized S100S were frac­
t; onated by reverse phase hi gh performance 1 i qui d chromatography. Di gests of
the unmodified S100S contained large amounts of undigested protein, while
those of oxidized S100S contained no detectable undigested protein. The
aborbance of the effl uent at 215 nm is shown in Fi gure 88. Seven pool s con­
taining peptides were recovered from this separation, and the amino acid com­
posi ti ons and recoveri es of these pepti des are shown in Tabl e 2. These pep­
ti des account for the enti re S100S mol ecul e. An assortment of short pepti des
(fracti on numbers 1 and 2) were deri ved from resi dues 24-34 whi ch i ncl ude fi ve
lysine residues. A large peptide containing residues 34-91 was recovered,
indicating that lysine 48 and lysine 54 were relatively insensitive to diges­
tion with trypsin. These results are similar to those reported by Isobe and
Okuyama (34).
Limited amino acid sequence analysis of peptides from cyanogen bromide
and tryptic digests of S100S were performed using automated Edman degrada­
ti on. The ami no termi nal sequences of cyanogen bromi de pepti des 80-91 and 58-
74 and of trypti c pepti de 6-20 were consi stent wi th the sequences reported by
Isobe and Okuyama (34). A compl ete summary of the ami no aci d sequence data for
S100S peptides appears in the Appendix.
S100 proteins were isolated from human and rat brains using affinity­
based adsorption chromatography on phenothiazine-Sepharose. Human brain
'S100 proteins were isolated from crude S100 fraction prepared according to
Watterson et al • (36). Foll owi ng chromatography on phenothi azi ne-Sepharose,
the S100 pool was fractionated on �80ndapak phenyl as described for bovine
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S100. Two peaks of u1 travi 01 et absorbi ng materi a1 e1 uted from the col umn at
36% acetoni tri 1 e, and one peak e1 uted at 40% acetoni tri 1 e in the mobile phase.
The ami no aci d composi ti ons of each of these pool sis shown in Tab1 e 3. Each of
these species of human S100 was tested for immunoreactivity with antisera
raised against performic acid oxidized bovine S100a. As shown in Figure 9,
all three species of S100 reacted to varying degrees with this antiserum.
S100 protei n was also i sol ated from rat bra ins exactly as descri bed for bovi ne
brai ns , Chromatography on �Bondapak phenyl reveal ed two peaks of absorbance
which eluted at 34% acetonitrile. Two fractions of the effluent were col­
lected and the amino acid compositions of these fractions are shown in Table
3. These ami no aci d composi ti ons are simi 1 ar to but di sti nct from those of the
bovine or human proteins.
Immunological Studies of S100a and S100S
In order to develop immunological tools for purified S100a and SlOOp,
various immunization procedures were used to prepare antisera in rabbits.
Performic acid oxidized S100a and S100S were injected subcutaneously in the
backs of rabbits using the protocol described in Materials and Methods. This
protocol has been shown to generate antisera against ca1modu1 in in a
reproducible fashion (86). The responses of rabbits to immunization with
performic acid oxidized S100s are shown in Figure 10. In direct radioim­
munoassays, consecuti ve sera from these rabbi ts bound i ncreas i ng amounts of
125I-S100p. The responses of rabbits to immunizations with performic acid
oxidized S100a are shown in Figure 11. Consecutive sera collected during the
first 70 days following the initial injections of these rabbits bound in­
creasing amounts of 125I-S100a antigen in direct radioimmunoassays. The
amount of anti gen bound to sera co11 ected after day 70 was lower than that for
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earl ier sera. Sera collected after day 90 again showed an increasing abil ity
to bind antigen, as shown in Figure 11.
In competitive inhibition assays, antisera from rabbits injected with
performic acid oxidized S100(3 did not react with bovine brain calmodul in or
rabbit skeletal muscle troponin C, as shown in Figure 12. The amount of S100(3
necessary to inhibit 50% of the binding of 125I-S100(3 to the first serum from
rabbi ts injected wi th performi c aci d oxi di zed S100f3 was fi fty-fol d lower than
that amount of S100a. As shown in Fi gure 12, however, the fi fth serum showed
no di scrimi nati on between the two protei ns. In contrast, anti sera from rab­
bi ts i nj ected wi th performi c aci d oxi di zed S100a showed an approximate 800-
1000 fold specificity for S100a over S100f3, as shown in Figure 13. This
specificity was stable for sera collected over a period of several months. It
is not cl ear whether the 0.1-0.2% reacti on of these anti sera wi th S100f3 is due
to contami nati ng S100f3 or to a small popul ati on of anti body mol ecul es whi ch do
not discriminate between S100a and S100f3.
Two rabbits were injected with unoxidized S100f3 according to protocol s
of Watterson et al. (185). Antisera from these rabbits showed a high reac­
tivity with 125I-S100f3 in direct radioimmunoassays as shown in Figure 14.
However, these anti sera di d not di scrimi nate between S100a and S100f3 in com­
petitive inhibition radioimmunoassays (Figure 15).
In order to test the feasibility of generating a site-directed antiserum
for S100(3, we synthesi zed the tri decapepti de MEl3B: Met{ O)-Al a-Phe-Val-Al a­
Met{O)-Ile-Thr-Thr-Ala-Cys{ACM)-His-Glu-NH2• This peptide encompasses
residues 74-86 of S100f3, a region which contains eight amino acid sequence
differences from S100a. The synthetic peptide ME13B was crosslinked to
chicken ovalbumin using glutaraldehyde according to the method described by
Audibert et al. (184). The ME13B-ovalbumin conjugate was injected sub-
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cutaneously accordi ng to the schedul e shown in Fi gure 16. Sera from both of
these rabbits show increasing ability to bind 125I_S100S, as illustrated in
Fi gure 16. These resul ts suggested that anti sera reacti ng wi th S100S coul d be
produced usi ng a syntheti c pepti de immunogen. Further studi es of syntheti c
immunogens for S100S have been initiated to develop a library of site­
directed antisera.
Phenothiazine Binding to Calcium Modulated Proteins
Phenothiazine-Sepharose 4B resin was used to rapidly screen proteins
for interactions with phenothiazines. Bovine brain calmodulin or chicken
gi zzard cal modul in whi ch was i odi nated accordi ng to the procedure of Ri chman
and Klee (180), bound to phenothiazine-Sepharose in calcium-containing
buffer and was eluted with buffer containing chelator. The amount of cal-
modul inbound increased 1 i nearly wi th the amount of phenothi azi ne-Sepharose
resin, reaching saturation at approximately 60-70% of the total radioac­
tivity, as shown in Figure 17. The binding of 125I-calmodul in to
phenothi azi ne-Sepharose increased over an i ncubati on peri od of 0-30 mi nutes
and was unchanged after 45 mi nutes for at 1 east 4 hours. All i ncubati ons were
performed for 60 minutes at room temperature. The binding of 125I-calmodul in
to phenothiazine-Sepharose was identical at pH 7.0, 7.4 and 8.0.
Because iodinated calmodul in was a useful tool in radioimmunoassays and
immobilized phenothiazine binding assays, we investigated the site of
i odi nati on by 1 actoperoxi dase and by chl orami ne Tin the absence and presence
of calcium. Bovine brain calmodul in contains two tyrosines, at position 99 in
the third domain and at position 138 in the fourth domain. Bovine brain cal­
modul in was i odi nated accordi ng to a modi fi cati on of the method of Ri chman and
Klee (180) using lactoperoxidase either in the presence of CaC12 or EGTA. In
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addition, ca1modu1 in was iodinated using a chloramine T procedure (182) ac­
cordi ng to the protocol of Van E1 di k and Watterson (176). Fo 11 owi ng removal
of the free Na 1251 by gel filtration, each of the iodinated proteins was
digested with trypsin in a mixture with 100�g unlabeled bovine brain cal­
modulin. The tryptic peptides were separated by chromatography on Whatman
ODS-3 resin according to methods described (176). The effluents were co1-
1 ected in 2 ml fracti ons, and the amount of radi oacti vi ty in each fracti on was
measured. Tryptic peptide standards were iodinated using the chloramine T
procedure (182), and the retenti on times of the i odi nated standard pepti des
were measured in separate experiments under chromatographi c condi ti ons i den­
ti cal to those for the trypti c di gests. Accordi ng to the pepti de nomencl ature
of Watterson et al. (32), peptide T-5B contains tyrosine 99, and peptide T-1B
contains tyrosine 138. Figure 18 shows the distribution of 1251 in calmodul in
after lactoperoxidase iodination in the presence of calcium. In this case
-80% of the radi oacti vi ty recovered was found ina peak whi ch comi grated wi th
"
i odi nated T-5B. The remai ni ng 20% of the radi oacti vi ty recovered was found in
T-1B. Similar results were obtained for iodination using chloramine T or
usi ng 1 actoperoxi dase in the presence of EGTA. The overall recovery was 81-
89% of the radioactivity applied to the column.
Various purified calcium modul ated proteins were tested for the abil ity
to block iodinated calmodulin binding to phenothiazine-Sepharose. Figure
19A shows the inhibition curves for calmodulin isolated from various animal
and p1 ant sources. All of these calmodul ins blocked the bi ndi ng of i odi nated
vertebrate calmodulin to immobilized phenothiazines. The amount of ver­
tebrate calmodul in required to inhibit 50% of the 125I-calmodul in binding was
33±6 (mean±SEM) pmol, determi ned in fourteen separate experiments, and that
amount for pl ant cal modul ins was 40±8 (mean±SEM) pmol , determi ned in four ex-
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periments. Results for rabbit skeletal muscle troponin C, bovine brain S100S
and carp parvalbumin are shown in Figure 19B. Troponin C and S100S blocked
125I-calmodulin binding to the immobilized phenothiazines, but parvalbumin
showed no i nhi bi ti on. In other experiments, bovi ne brai n S100a i nhi bi ted ina
manner similar to S100S, while the chicken and rat vitamin D-dependent cal­
ci urn bi ndi ng protei ns showed no i nhi bi ti on. These resul ts i ndi cated that a
subclass of calcium modulated proteins interacted with immobilized
phenothiazines in the apparent relative order calmodulin>troponin
C>S100(l�S100�.
Purified S1008 and troponin C were also tested for the ability to in­
teract di rectly wi th phenothi azi ne-Sepharose conj ugates. The resu1 ts of an
experiment wi th bovi ne bra in S100S are shown in Fi gure 20. S100S (25 lJg) ad­
sorbed to a column (0.65 x 3.0 cm) containing phenothiazine-Sepharose con­
jugates in the presence of calcium and eluted with buffers conaining
chelator. The protein was not retained by the column when applied in the
presence of buffers containing calcium chelators. Identical results were ob­
tained for rabbit skeletal muscle troponin C. Although these results with im­
mobilized phenothiazines were indicative of drug-protein interactions, the
experiments were based on a calcium dependent adsorption to an immobilized
matrix.
In order to determine whether the activity of proteins in immobilized
phenothi azi ne bi ndi ng assays refl ected the bi ndi ng of phenothi azi ne drugs in
sol uti on, bi ndi ng experiments were performed usi ng the method of Hummel and
Dreyer (178). As shown in Fi gure 21, the protei n sampl e wi th bound drug el uted
as a peak of absorbance at the voi d vol ume of the gel fi 1 trati on col umn. The
trough in Figure 21 corresponded to the depletion of drug from the buffer,
caused by drug bi ndi ng to the protei n. The area of thi s trough represented the
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amount of drug bound to the protei n sampl e. In order to cal cul ate the amount
of drug represented by the area of the trough, it was necessary to cal ibrate
the response of the detector to known amounts of drug. An exampl e of thi s ex­
ternal calibration is shown in Figure 22. At each chlorpromazine concentra­
ti on, the response of the detector was 1 i near wi th the amount of drug, and the
amount of drug correspondi ng to the area of the trough was cal cul ated usi ng
thi s rel ati onshi p , as shown in Fi gure 22. The amount of drug represented by
the trough was also calculated by internal calibration. By adding excess drug
to the sampl e of protei n, the area of the trough was reduced or converted to a
peak, as illustrated in Figure 23. The relationship between the areas of
these peaks or troughs and the amount of excess drug added to the sampl e was
1 i near, as shown in Fi gure 24. The amount of drug bound to the protei n is equal
to the amount of excess drug requi red to bri ng the area of the trough to zero,
shown by the dashed line in Figure 24. The values for the amount of chlor­
promazi ne bound to bovi ne brai n calmodul in cal cul ated by external and i nter­
nal cal ibrati ons di ffered by <5% below 20 llM drug and <20% at hi gher drug con­
centrations.
The binding of chlorpromazine by bovine brain calmodulin was measured
over a range (0.5-100 llM) of chl orpromazi ne concentrati ons. Us i ng the method
of Hummel and Dreyer (178) all owed the measurement of the number of mol es of
drug bound per mol e of protei n at thermodynami c equi 1 i bri urn for each drug con­
centrati on. The resul ts of these measurements are shown in Fi gure 25. In the
presence of calcium calmodulin bound 5-6 moles of drug per mole of protein
with an apparent dissociation constant of 17-20 llM. In the presence of 4 mM
MgC12 and 1 mM EGTA, calmodulin bound less than 0.5 moles of drug per mole of
protein (Figure 25).
Spinach calmodulin and Dictyostelium calmodulin also bound chlor­
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promazine under equilibrium conditions, as shown in Table 4. These cal­
modul ins bi nd up to 4-5 mol es of drug per mol e of protei n. In order to eval uate
these data in terms of the comparati ve structure of the protei ns, the ami no
acid sequence of Dictyostelium calmodulin was investigated. Dictyostelium
calmodulin (provided by M. Clarke, Newark, N.J.) was purified as described
(51) and subj ected to chromatography on a lJBondapak phenyl col umn as
described in Materials and Methods. The purified protein was treated with
protease from mouse submaxillary gland, and the resulting peptides were
separated by reverse phase 1 i qui d chromatography as shown in Fi gure 26. Four
peptides were isolated from fractions of the effluent, designated 16,17,18,
and 21. The amino acid compositions of these peptides are shown in Table 5.
The ami no aci d sequence of the fi rst 36 res i dues of pepti de 17 were
elucidated, and the peptide was found to be homologous to residues 107-148 of
other calmodul ins, as shown in Table 2. The amino acid sequence determination
data are shown in the Appendix.
Other proteins were tested for their ability to bind chlorpromazine
under equilibrium conditions. These results are summarized in Figure 27.
Rabbit skeletal muscle troponin C bound up to 2 moles of drug per mole of
protei n at 50 and 100 lJM chl orpromazi ne, whi 1 e S100a. and S100S bound up to 1
mole of drug per mole of protein. Carp parvalbumin bound very little chlor­
promazi ne, even at 100 lJM chl orpromazi ne. Thi s apparent order of bi ndi ng ac­
tivities was similar to that observed using the immobilized phenothiazine
binding assay: calmodulin>troponin C> S100a.�S100S.
Phenothiazine Binding to Fragments of Calmodulin
Peptides and whole digests of bovine brain calmodulin were tested for
their abilities to interact with immobilized phenothiazines. Digestion of
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vertebrate calmodul in with trypsin or cyanogen bromide abol ished the abil ity
of the protein to block 1251-calmodulin binding to phenothiazine-Sepharose
as shown in Figure 28. Tryptic digestion of citraconylated calmodulin
produced a mixture of polypeptides which inhibited 1251-calmodulin binding
to phenothi azi ne-Sepharose conj ugates to the same extent as nati ve protei n,
as shown in Figure 29. Digests of calmodulin using the protease from mouse
submaxillary gland also inhibited 1251-calmodulin binding to immobilized
phenothiazines, as shown in Figure 30.
Bovine brain calmodulin was digested with mouse submaxillary gland
protease, and individual peptides were isolated by reverse phase liquid
chromatography. The ami no aci d composi ti ons of these pepti des are shown in
Table 6. Samples of each of these peptides were tested for their activity in
immobil i zed phenothi azi ne bi ndi ng assays. Pepti de 1-90 reduced the bi ndi ng
of iodinated calmodulin to phenothiazine- Sepharose by 22%. All other pep­
tides showed no detectable activity in this assay. Synthetic peptides whose
ami no aci d sequences covered two regi ons of cal modul in were tested for thei r
activity in immobilized phenothiazine binding assays. The amino acid se­
quences of these peptides are listed in Table 7. Peptide FF25 comprises
residues 68-93 of the bovine brain calmodulin sequence and peptide AF20
covers residues 73-93. Both are in the interdomain region between domains 2-
3. Peptide AE21 encompasses residues 102-123, the interdomain region between
domains 3 and 4. As shown in Figure 31, none of these peptides inhibited 1251_
calmodulin binding to phenothiazine-Sepharose at a 200 to 500 fold molar ex­
cess of pepti de. Mi xi ng AE21 and FF25 al so di d not produce an acti ve speci es
in this assay (Figure 31).
Peptides from the submaxillary gland protease digestion of calmodulin
were tested for drug binding using Hummel-Dreyer analysis at 10 and 100 �M
page 47
chl orpromazi ne, and the resul ts are summari zed on Table 8. Pepti de 1-90 was
able to bind chlorpromazine to 5% of the level of the native protein. Smaller
peptides displayed even less drug binding activity. Peptide 1-37 bound 2% of
the amount of chl orpromazi ne bound by the intact protei n , whi 1 e pepti de 107-
148 bound drug at the 1 evel of 1% that of the intact protei n at the hi gher drug
concentration, 100 �M chlorpromazine.
Relationship between Drug Binding and Protein Binding Activities of Cal­
modulin
The correlation between phenothiazine binding and protein binding ac­
tivity of calmodul in was tested in several ways. First, performic acid ox­
idized calmodul in retained activity in immobil ized phenothiazine binding ex­
periments as shown in Figure 32. However, performic acid oxidized calmodul in
does not activate phosphodiesterase, although it is not clear if it can in­
hibit calmodulin activation of phosphodiesterase (185). In equilibrium
binding studies, performic acid oxidized calmodul in bound 1.3 moles of chlor­
promazi ne per mol e of protei n only at 100 �M drug, as shown in Fi gure 27. These
data suggest that performi c aci d oxi dati on reduces the affi ni ty of ca 1 modul in
for chlorpromazine but does not eliminate its ability to interact with the
drug. After digestion with submaxillary gland protease, calmodulin retained
drug bi ndi ng acti vi ty (Fi gure 30) , but di d not acti vate phosphodi esterase, as
shown in Figure 33.
Second, bovine brain calmodul in was digested with increasing amounts of
tryps in for 14 hours, and the di gests were measured for phosphodi esterase ac­
tivator activity and for immobilized phenothiazine binding activity. As
shown in Fi gure 34, immobil i zed phenothi azi ne bi ndi ng is lost after di gesti on
with a smaller amount of trypsin than is phosphodiesterase activator ac-
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tivi ty.
Third, the inhibition of calmodulin stimulated phosphodiesterase by
phenothiazines was tested under conditions of temperature, ionic strength,
and pH i denti cal to those for equi 1 i bri urn bi ndi ng experiments. The resul ts
are shown in Fi gure 35. The concentrati on of chl orpromazi ne needed to block
50% of the activator activity was approximately 27 �M.
Fourth, chlorpromazine was included in the incubation of 125I_cal_
modul in in a gel overl ay experiment. The resul ts of thi s experiment are shown
in Figure 36. Samples of chicken gizzard myosin 1 ight chain kinase, rabbit
skel etal muscl e phosphoryl ase ki nase, and mi crosomal and supernatant subcel-
lular fractions of chicken embryo fibroblasts were subjected to
polyacrylamide gel electrophoresis in the presence of sodium dodecyl sul­
fate. Following electrophoresis, the gels were washed and stained as
described in Materials and Methods. 125I-calmodulin was preincubated for
thirty minutes at room temperature in buffer containing 0, 10 �M or 100 �M
chlorpromazine in the presence of calcium, and these solutions were subse-
quently incubated wi th i denti cal polyacryl ami de gel s , As shown in Fi gure 36,
results for 0 and 10 �M chlorpromazine were indistinguishable, while 100 �M
chlorpromazine inhibited most of the calcium dependent binding. Some, but
not all , of the protei ns in the mi crosomal fracti on whi ch show bi ndi ng in the
presence of EOTA also show binding in 100 �M chlorpromazine.
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DISCUSSION
As part of an effort to characteri ze structural and functi ona1 domai ns
on cal modu1 in and other cal ci urn modu1 ated protei ns, the experiments
presented in this thesis were designed to investigate the interactions
between phenothi azi ne drugs and cal ci urn modu1 ated protei ns , The resul ts of
these studies support three general conclusions.
Fi rst, a subcl ass of cal ci urn modu1 ated protei ns bi nds phenothi azi nes in
a cal ci urn dependent manner. Quanti tati ve measurements in sol uti on at ther­
modynamic equilibrium established the stoichiometry and affinity of drug
binding for several structurally related calcium modulated proteins. In ad­
di ti on, immobi1 i zed phenothi azi nes were used to i sol ate S100a and S100S from
bovine brain, and these proteins were characterized structurally and im­
munologically.
Second, the bi ndi ng of phenothi azi nes by cal modul in appears to be a com­
p1 ex phenomenon that i nvol ves mul ti pl e sites and that requi res an extended
region of the calmodulin molecule. Chemically modified calmodulin,
proteo1yti c and syntheti c fragments of cal modu1 in, and structural analogs of
bovine brain ca1modu1 in had drug binding properties different from the native
protein.
Third, within the limitations of the methods employed, phenothiazine
binding to calmodulin correlated with inhibition of calmodulin's enzyme ac­
ti vati on and protei n bi ndi ng functi ons. However, several resu1 ts suggested
that drug bi ndi ng and protei n bi ndi ng acti vi ti es of cal modul in cou1 d be di s­
sociated under certain experimental conditions. The following discussion
contai ns a secti on on the bi ochemi cal and immuno1 ogi cal character; zati on of




SlOO proteins were isolated from cow, rat, and human brain extracts using af­
fi ni ty-based adsorpti on chromatography on phenothi azi ne-Sepharose con­
jugates. Two po1ypepti de components of bovi ne brai n SlOO were separated by
preparati ve reverse phase hi gh performance 1 i qui d chromatography. Accordi ng
to ul travi 01 et absorpti on spectra, ami no aci d ana1ysi s, pepti de maps and par­
tial amino acid sequence analysis, SlOOa and SlOOS isolated from bovine brain
using immobilized phenothiazines were indistinguishable from the polypep­
tides isolated by Isobe et al. (33-34). There have been no reports of quan­
titative recovery of SlOOa and SlOOS from bovine brain because no specific
functi ona1 parameter cou1 d be moni tored throughout the preparati on. Si nce no
functi on of SlOOa and SlOOS has been estab1 i shed, immunochemi cal methods are
the most useful methods for detection of the proteins.
In order to produce antisera against SlOOa and SlOOs, we used the
procedure of Van El di k and Watterson (86). Thi s method estab 1 i shed the prece­
dent for reproducible production of antisera against ca1modul in, and the im­
munoreactive site on calmodulin for one of these antisera was characterized
in detail. Antisera from rabbits injected with performic acid oxidized SlOOa
showed a speci fi ci ty for SlOOa over SlOOS. Thi s speci fi ci ty was seen in sera
collected during the first nine weeks following the initial injection. Rab­
bits injected with performic acid oxidized SlOOt:S initially produced antisera
with relative specificity for SlOOt5, but this specificity was reduced over a
period of ten weeks. Injections of unoxidized Sl0013 in rabbits produced an­
tisera with a high titer to S100S but with no discrimination between SlOOa and
S100S.
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A more recent approach has been to raise antisera against synthetic
peptides modeled from regions of the SlOO� molecule which are dissimilar to
SlOOa. Such anti sera mi ght react wi th a uni que regi on of the nati ve protei n.
Thi s method of engi neeri ng anti sera has been used successfully by Watterson
etal. (185) for the calmodulin molecule. In our studies, peptide-ovalbumin
conj ugates have eli ci ted a 1 imi ted response to SlOOS in two rabbi ts . These
results suggest the feasibility of producing antisera which react with SlOOS
by using synthetic peptides as immunogens.
Anti sera agai nst SlOO protei ns were ori gi nally produced by Levi ne and
Moore (186) using crude bovine SlOO coupled to methylated bovine serum al­
bumin. SlOO has been characterized as a very poor immunogen (125,186). In
contrast, we found that purifi ed SlOOS is an excell ent anti gen and produced a
high titer antiserum. The difficulty in obtaining sera specific for SlOOS
over SlOOa may be due to the hi gh structural homology between the two
proteins. Haan et al. (187) have reported the production of monoclonal an­
tibodies against SlOO. However, even these monoclonal antibodies apparently
react with both SIOOa and SIOOS. Thus, the use of synthetic peptides to
produce si te di rected anti sera seems to be a rati onal approach to generati ng
highly specific antibodies.
Drug-Protein Interactions
The isolation of SlOOa and SlOOS using an immobilized phenothiazine led
to the finding that certain calcium modulated proteins interact with
phenothiazines. Calmodulin, troponin C, SlOOa and SlOOS interact with im­
mobilized phenothiazines (113) and bind chlorpromazine in solution. Our
studies of parvalbumin and vitamin D-dependent calcium binding proteins in­
di cate that thi s drug-protei n i nteracti on is not a general feature of cal ci urn
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modu1 ated protei ns , The EF hand cal ci urn bi ndi ng structure alone cannot ac­
count for drug binding activity since parval bumi n (26) and vitamin D-depen­
dent calcium binding protein (30) both contain these structures yet do not
bind phenothiazines. Parva1bumin also contains an internal hydrophobic
domain (12,26), but this domain is evidently not sufficient for the protein to
bind phenothiazines under the conditions of our assays. In contrast, a
cationic drug binding domain on bovine serum albumin is accessible to
phenothiazine interaction (139,146).
The structural requirements of the drug binding domains on calmodulin
were addressed by examining drug binding activities of calmodul in digests and
purified peptides. Tryptic and cyanogen bromide digestion destroyed the
ability of calmodulin to block 125I-calmodulin binding to phenothiazine­
Sepharose. However, digestion of calmodulin with mouse submaxillary gland
protease or of citraconylated calmodulin with trypsin resulted in digests
which retained the ability to inhibit calmodulin binding to immobilized
phenothiazines. These digests showed activities similar to calmodulin on a
molar basis. This indirect study implicated regions of calmodulin which are
different between complete tryptic digestion and cleavage only at arginine
residues. These encompass domain 1 and the interdomain region between
domains 2-3. Synthetic peptides in this interdomain region showed no ac­
ti vi ty in the immobil i zed drug bi ndi ng assay. However, these pepti des were
relatively short and did not encompass a complete structural domain of the
calmodulin molecule.
Several 1 arge fragments of calmoduli n retai ned the abi 1 i ty to interact
with immobilized phenothiazines. One of these (116) contained the carboxy
termi nal regi on as judged by immunoreacti vi ty with the site speci fi c anti sera
of Van E1 di k and Watterson (86). Head et al . (188) ; denti fi ed a fragment from
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a cyanogen bromide digest of calmodul in which bound to immobil ized
phenothiazines in the presence of calcium and was eluted with EGTA. That
fragment also encompassed part of the caboxy terminal half of the molecule
(residues 77-124). However, the adsorption of a fragment of ca1modu1 in to im­
mobilized phenothiazines does not necessarily imply that the fragment has
stoichiometric, high affinity drug binding properties in solution. An in­
herent 1 imi tati on of both of these studi es (116,188) is that the bi ndi ng af­
finity was not quantitated by elution with free phenothiazine.
In order to quantitate phenothiazine binding, several large fragments
of calmodulin were tested for their ability to Bind chlorpromazine in solu­
tion under equilibrium conditions. The isolated peptide 1-90 showed some
bi ndi ng to chl orpromazi ne in sol uti on. A1 though not stoi chi ometri c , thi s was
the first demonstration that an isolated peptide from calmodulin retained
drug binding capacity in solution. However, even peptide 1-90, which in­
cluded nearly two-thirds of the protein had only 5% of the drug binding ac­
tivity of the intact protein. These data indicate that chlorpromazine
bi ndi ng is not a simpl e phenomenon and suggests that hi gh affi nity, cal ci urn
dependent drug binding resides in an extended region of the calmodulin
mol ecul e. For exampl e, an i nteracti on between two hal ves of the protei n may
be necessary for high affinity drug binding. The EF hand model (12) does not
predict the nature of the interaction between the amino terminal hal f
(domains one and two) and the carboxy terminal half (domains three and four).
The x-ray crytall ographi c structure of calmodul in may reveal these rel ati on­
ships.
Results of several experiments suggested that the phenothiazine drug
binding activity and enzyme activator activity of calmodulin were dis­
sociable. Performic acid oxidized calmodulin retained the ability to in­
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teract with immobilized phenothiazines but did not activate phos­
phodiesterase. In solution, performic acid oxidized calmodulin displayed
the abi 1 i ty to bi nd more than 1 mol e of ch1 orpromazi ne per mol e of protei n at
100 llM drug. Thi s 1 eve1 of drug bi ndi ng is 1 ess than that of the unmodi fi ed
protein but appears to be sufficient to inhibit iodinated ca1modu1 in binding
to immobi1 i zed phenothi azi nes. Performi c aci d oxi dati on quanti tati ve1y con­
verts the methionines in calmodulin to methionine sulfone (175). This
modification may allow calmodulin to retain some of its secondary structure
and to adsorb to phenothiazine-Sepharose conjugates, while abolishing cal­
modulin's ability to activate phosphodiesterase. In contrast, when cal­
modu1 in was di gested wi th i ncreasi ng amounts of trypsi n, immobi1 i zed
phenothi azi ne bi ndi ng was lost wi th a lower concentrati on of tryps in than was
phosphodiesterase activator activity. This experiment has limitations
because it was a compari son of two assays whi ch vari ed in thei r sensi ti vi ti es
and in their abilities to discriminate activities. Nevertheless, the data
obtained from partial trypsin digestion and from performic acid oxidation
suggested that di fferent modi ficati ons of cal modul in 1 ed to the di fferenti a1
loss of its drug binding and enzyme activator functions.
Equilibrium binding studies of bovine brain calmodulin and ch1or­
promazi ne reveal ed a maximal bi ndi ng of 5-6 mol es of drug per mol e of protei n
in the presence of calcium. In the presence of 1 mM EGTA and 4 mM magnesium,
1 ess than one mol e of drug bound per mol e of protei n (Fi gure 25). Hal f maximal
binding of chlorpromazine occured at 17-20 llM drug in the presence of calcium.
Between 10 and 15 llM chlorpromazine, there was a slight inflection in the
binding curve, suggesting biphasic drug binding. However, these data are not
suffi ci ent to establ ish two di sti nct popu1 ati ons of bi ndi ng si tes. It is si g­
nificant that troponin C from rabbit skeletal muscle bound up to approx-
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imately 2 mol es of chl orpromazi ne per mol e of protei n (Fi gure 27). Troponi n C
and calmodulin have 60% sequence homology (32), but the two proteins ap­
parently have di fferent stoi chi ometri es of chl orpromazi ne bi ndi ng. Spi nach
calmodulin may have slightly different affinity for chlorpromazine than the
bovine protein (Table 4, Figure 25), but more data are necessary to establish
this difference. These results with bovine brain calmodulin and its struc­
tural analogs do indicate that chlorpromazine binding to calmodulin is a com­
plex phenomenon involving multiple sites of interaction.
Several explanations that have been raised for other drug-protein in­
teractions (189-191) may apply to the complex calmodulin-phenothiazine in­
teracti ons. Mol ecul es of drug coul d bi nd ina cooperati ve manner if hi gher
drug concentrati ons cause an unfo1 di ng of the ca1moduli n structure. Al terna­
tive1y, additional drug molecules may interact with drugs already bound to
the protein. The stacking of drug molecules on calmodulin has been suggested
by evi dence for drug-drug i nteracti ons in nucl ear magneti c resonance experi­
ments (192-193) , but these measurements were made at mi 11 imo1 ar drug concen­
trations, near the critical micellar concentration of several phenothazines
( 194). The concentrati ons of ch1 orpromazi ne used in our experiments are at
least an order of magnitude below the critical micellar concentration for
chlorpromazine in 0.15 M sodium chloride (194). However, this does not ex­
clude the possibility that small aggregates of drug molecules in solution
bind to calmodulin. In fact, we observed lower solubility of chlorpromazine
at concentrations above 200 �M in the buffers with a total ionic strength
above 200 mM.
The complex nature of the chlorpromazine binding to calmodulin is
reminiscent of the interactions between serum albumins and dyes. Horowitz
and Klotz (189) observed that p-ami nophenyl mercuri c acetate bound to bovi ne
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serum albumin in a biphasic manner at pH 6.0-6.4. Up to 0.56 moles of dye per
mol e of protei n bound ina 1 i near fashi on at 0.1 llM free dye. Above 15 llM dye,
the mol es of dye per mol e of protei n increased to val ues above 3 over a narrow
range of dye concentrations. The interpretation of these data was similar to
our analysis of the calmodul in-phenothiazine interaction. The dye may induce
an unfolding of the albumin molecule, or interactions among adjacent dye
mol ecul es may thermodynami cally favor the bi ndi ng of addi ti onal dye
mol ecul es. These sorts of model shave al so been used to expl ai n the bi ndi ng of
various organic ions to serum albumins (190-191).
The binding of phenothiazines by calmodulin was qualitatively dis­
similar to the binding of phenothiazines by glutamate dehydrogenase (145).
Whi 1 e the apparent di ssoci ati on constants for the bi ndi ng of phenothi azi nes
to gl utamate dehydrogenase were in the mi cromo1 ar range, the bi ndi ng of the
drugs was not dependent on cal ci urn ions. These di ssoci ati on constants were
correlated to kinetically-derived constants for enzyme inhibition.
Phenothi azi nes i nhi bi t the acti vi ty of gl utamate dehydrogenase, and Veronese
et a1. (145) provided evidence that drug binding was related to the binding of
the natural ligands, NADH and GTP, to the enzyme. The possibility remains
that phenothi azi nes mimi c the bi ndi ng of some naturally occurri ng 1 i gand to
calmodulin.
The binding of chlorpromazine to calmodul in correl ated with the inhibi­
tion of ca1modul in function, within the 1 imits of the experimental design. As
shown in Figure 35, chlorpromazine blocked the activation of cyclic
nucleotide phosphodiesterse by calmodulin. The concentration of chlor­
promazine necessary for 50% inhibition of activator activity was 27 llM. The
temperature, ionic strength and pH of these measurements were identical to
those used for equi 1 i bri urn drug bi ndi ng mesurements. Under these condi ti ons,
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the val ue 27 llM is not si gni fi cantly di fferent from the apparent di ssoci ati on
constant of 17 -20 llM for chl orpromazi ne bi ndi ng to calmodul in. However, thi s
correlation does not exclude the possibility that only a population of drug
binding sites are linked to functional inhibition.
In the gel overl ay experiments shown in Fi gure 36, 10 llM chl orpromazi ne
did not block the interaction of 12SI-calmodulin with binding proteins. In
contrast, 100 llM chlorpromazine was sufficient to inhibit almost all of the
binding of calmodulin to various proteins. These data indicate that 10 and
100 llM are the 1 imi ts of the range of effecti ve chl orpromazi ne concentrati ons
under these conditions. This finding is consistent with an apparent dis-
sociation constant for chlorpromazine binding of 17-20 llM and with an ap­
parent ICSO for phosphodi esterase acti vator i nhi bi ti on of 27 llM. In overl ay
inhibition experiments the concentration of drug required for SO% inhibition
was not ti trated preci sely because of the quantal nature of the procedure. In
addition, the exact affinity and stoichiometry of chlorpromazine binding to
iodinated calmodulin are not known.
The results presented in this thesis have several implications for
biological studies. The finding that chlorpromazine binding to ca1modu1 in is
a complex phenomenon with multiple sites of interaction suggests that the
bi 01 ogi cal effects of low, non-cytotoxi c doses of phenothi azi nes may not be
due to the antagonism of calmodulin action. Levels of phenothiazine drugs
sufficient to bind to calmodul in in substoichiometric amounts do not neces-
sarily imply that the function of calmodulin has been altered. In the
presence of multiple classes of phenothiazine binding proteins and subcel-
I
1 ul ar structures, the extracell ul ar concentrati on of drug may not refl ect the
true intracellular concentration of drug available to calmodulin. The
availability of calmodulin in vivo to the drug is also unknown.
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The studi es presented here provi de the necessary foundati on for our cur­
rent attempts to elucidate the molecular basis of specific drug-protein in­
teractions. Our recent approach combines measurements of the equilibrium
binding of drugs with the identification of covalent drug-protein adducts
(168).
By studying the drug binding properties of calmodul in and re1 ated ca1-
ci urn modul ated protei ns, these i nvesti gati ons may provi de a framework for the
rati onal desi gn of new drugs. Of parti cu1 ar interest are compounds that an­
tagonize specific biological effects of calcium. Recently, the family of
drugs whi ch act as cal ci urn channel blockers has gai ned promi nence in c1 i ni cal
card; 01 ogy (195). However, the se1 ecti ve acti on of these drugs requi res the
adjustment of dosage to block only a porti on of the cal ci urn i on channel s . An
alternate approach to the antagonism of calcium action would involve the
selective inhibition of specific receptors for calcium ions intracellu1ar1y.
For example, inhibitors of tissue specific calcium modulated proteins, such
as cardi ac troponi n C, may have fewer systemi c effects than cal ci urn channel
blockers. Compounds which block the calmodulin activation of some enzymes
but not others might be useful in treating pathophysiological states which
involve calcium mediated responses.
The design of specific antagonists of calcium modulated proteins will
rely on a detai 1 ed know1 edge of the mol ecu1 ar physi 01 ogy of these protei ns.
The studies presented in this thesis add to our knowledge of the molecular




1. Flockhart, D.A. and Corbin, J.D. (1982) CRC Crit. Rev. Biochem.
12:133-186.
2. Nimmo, H. G. and Cohen, P. (1977) Adv. Cyc. Nuc. Res. �: 145-266.
3. Ebashi, S., Endo, M. and Ohtsuki , 1. (1969) Q. Rev. Biophys. �:351-384.
4. Volpe, J.J. and Vagelos, P.R. (1973) Annu. Rev. Biochem.42:21-60.
5. Vanaman, T .C., Wakil, S.J. and Hill, R.L. (1968) J. Biol. Chern.
243:6409-6419.
6. Vanaman, I.C., Wakil, S.J. and Hill, R.L. (1968) J. Biol. Chern.
243:6420-6431.
7. Brew, K. and Hill, R.L. (1975) Rev. Physiol. Biochem. Phar-
macol.72:102-158.
8. Brew, K., Vanaman, T.C. and Hill, R.L. (1968) Proc. Natl. Acad. Sci.
USA 595:491-497.
9. Klee, W.A. and Klee, C.B. (1970) Biochem. Biophys. Res. Commun.
39:833-841.
10. Gregol in, C. , Ryder, E. and Lane, M.D. (1968) J. Bi 01 • Chern. 243:4227-
4235.
11. Grego 1 in, C. , Ryder, E. and Lane, M.D. (1968) J. Bi 01 • Chern. 243:4236-
4245.
12. Kretsinger, R.H. (1980) CRC Crit. Rev. Biochem. 8:119-174.
2433:3978-3986.
13. Van Eldik, L.J., Zendegui, J.G., Marshak, D.R. and Watterson, D.M.
(1982) Intl. Rev. Cyt. l1_:1-61.
14. Kendrick-Jones, J., Szentkiralyi, LM. and Szent-Gyorgyi, A.G. (1976)
J. Mol. Biol. 104:747-775.
15. Hartshorne,D.J. andPersechini,A.J. (1980) Ann. N.Y. Acad. Sci.
356:130-141.
16. Conti, M.A. and Adelstein, R.S. (1981) J. Biol. Chern. 256: 3178-3181.
17. Hathaway, D.R., Eaton, C.R. and Adelstein, R.S. (1981) Nature 291:252-
254.
18. Cohen, P., Burchell, A., Foulkes, J.G., Cohen, P.T.W., Vanaman, T.C.,
and Nairn, A.C. (1978) FEBS Lett. 92:287-293.
page 60
19. Payne, M.E. and Soder1 ing, T .R. (1980) J. Bio1. Chern. 255: 8054-8056.
20. Ne1sestuen, G.l. (1976) J. Bio1. Chern. 251:5648-5656.
21. Ne1sestuen, G.L., Kisiel, W. and DiScipio, R.G. (1978) Biochemistry
17: 2134-2138.
22. Becker, J .W., Reeke, G.N., Wang, J.L., Cunningham, B.A. and Edelman,
G.M. (1975) J. Bio1. Chern. 250:1513-1524.
23. Matthews, B.W., Weaver, l.H. and Kester, W.R. (1974) J. Bio1. Chern.
249:8030-8044.
24. Dijkstra, B.W., Ka1k, K.H., Ho1, W.G.J. and Drenth, J. (1981) J. Mol.
Bio1. 147:97-123.
25. Verheij, H.M., Vo1werk, J.J., Jansen, LH.J.M., Puyk, W.C., Dijkstra,
B.W., Drenth, J. and de Haas, G.H. (1980) Biochemistry �:743-750.
26. Moews, P.C. and Kretsinger, R.H. (1975) J. Mol. Bio1. 91:201-228.
27. Collins, J.H., Greaser, M.l., Potter, J.D. and Horn, M.J. (1977) J.
Bio1. Chern. 252:6356-6362.
28. van Eerd, J.-P. and Takahashi, K. (1976) Biochemistry �:1171- 1180.
29. Fullmer, C.S. and Wasserman, R.H. (1981) J. Bio1. Chern. 256:5669-
5674.
30. Szebenyi, D.M.L, Obendorf, S.K. and Moffat, K. (1981) Nature,
294:327-332.
31. Wasserman, R.H., Corradino, R.A. and Taylor, A.N. (1968) J. Bio1.
Chern. 243:3978-3986.
32. Watterson, D.M., Sharief, F. and Vanaman, T.C. (1980) J. Bio1. Chern.
255:962-975.
33. Isobe, T. and Okuyama, T. (1981) Eur. J. Biochem. 116:79-86.
34. Isobe, T. and Okuyama, T. (1978) Eur. J. Biochem. 89:379-388.
35. Cheung, W.Y. (1980) Science 207:19-27.
36. Watterson, D.M., Harrelson, W.G., Keller, P.M., Sharief, F., and
Vanaman, T.C. (1976) J. Bio1. Chern. 251:4501-4513.
37. K1ee, C.B. and Vanaman, T.C. (1982) Adv. Prot. Chern. �:213-321.
38. Cook, W.J., Dedman, J.R., Means, A.R., and Bugg, C.E. (1980) J. Bio1.
Chern. 255:8152-8153.
39. Kretsinger, R.H., Rudnick, S.L, Sneden, D.A., and Schatz, V.B. (1980)
J. Bio1. Chern. 255:8154-8156.
page 61
40. Schreiber, W.E., Sasagawa, T., Titani, K., Wade, R.D., Malencik, D., and
Fischer, E.H. (1981) Biochemistry 20:5239-5245.
41. Burgess, W. B., lukas, T. L. , Marshak, D. R., and Watterson, D. M. (1983)
unpublished observation.
42. Dedman, J.R., Jackson, R.L., Schreiber, W.E., and Means, A.R. (1978) J.
Bio1. Chern. 253:343-346.
43. Grand, R.J.A., Sheno1ikar, S. and Cohen, P. (1981) Eur. J. Biochem.
113: 359-367 .
44. Jamieson, G.A., Bronson, D.O., Schachat, F.H., and Vanaman, T.C. (1980)
Ann. N.Y. Acad. Sci. 356:1-13.
45. Takagi, T., Nemoto, T. and Kani shi , K. (1980) Bi ochem. Bi ophys. Res.
Commun. 96:377-381.
46. Yazawa, M., Yagi, K., Toda, H., Kondo, K., Narita, K., Yamazaki, R.,
Sobue, K., Kakiuchi, S., Nagao, S., and Nozawa, Y. (1981) Biochem.
Biophys. Res. Commun. 99:1051-1057.
47. Iverson, D.B., Schleicher, M., Zendegui, J.G., and Watterson, D.M.
(1981) Fed. Proc. Fed. �. Exp. Bio1. 40,1738.
48. Schleicher, M., Iverson, D.B., Van E1dik, l.J., and Watterson, D.M.
(1982) in The Cytoskeleton in Plant Growth and Development (Lloyd, C.W.,
ed.) pp.85-106, Academic Press, london.
49. lukas, T.l., Schleicher, M. and Watterson, D.M. (1983) Fed. Proc.
42:2203.
50. Schleicher, M., lukas, T.J. and Watterson, D.M. (1983) submitted for
publication.
51. Bazari, W.l. and Clarke, M. (1981) J. Biol. Chern. 256:3598-3603.
52. Perry, S.V., Grand, R.J.A., Nairn, A.C., Vanaman, T.C., and Wall, C.M.
(1979) Biochem. Soc. Trans. 7:619-622.
53. Van Eldik, L.J., Piperno, G. and Watterson, D.M. (1980) Proc. Natl.
Acad. Sci. U.S.A.77:4779-4783.
54. Schl ei cher, M. , Zendegui, J. G., and Watterson, D. M. (1982) Fed. Proc.
Fed. Am. Soc. Exp. Bio1. �:503.
55. Grand, R.J.A., Nairn, A.C. and Perry, S.V. (1980) Biochem. J. 185:755-
760.
56. Cheung, W.Y. (1970) Biochem. Biophys. Res. Commun. 38:533-538.
57. Kakiuchi, S. and Yamazaki, R. (1970) Biochem. Biophys. Res. Commun.
41: 1104-1110.
page 62
58. Brostrom, C.O., Huang, Y.-C., Breckenridge, B.M. and Wolff, D.J.
(1975) Proc. Natl. Acad. Sci. U.S.A. 72:64-68.
59. Cheung, W.Y., Bradham, i..s., lynch, T.J., lin, Y.M., and Tallant, LA.
(1975) Biochem. Biophys. Res. Commun. 66:1055-1062.
60. Toscano, W.A., Westcott, K.R., laPorte, D.C., and Storm, D.R. (1979)
Proc. Natl. Acad. Sci. U.S.A. 76:5582-5586.
61. Salter, R.S., Krinks, M.H., Klee, C.B., and Neer, LJ. (1981) J. Bio1.
Chern. 256:9830-9833.
62. Nagao, S., Suzuki, Y., Watanabe, Y., and Nazawa, Y. (1979) Biochem.
Biophys. Res. Commun. 90:261-268.
63. B1um,J.J., Hayes, A., Jamieson, G.A., andVanaman,T.C. (1980)J. Cell
Biol. 87:386-397.
64. Dieter, P. and Marme, D. (1981) FEBS lett. 125:245-248.
65. Gopinath, R.M. and Vincenzi, F.F. (1977) Biochem. Biophys. Res. Com­
mun. 77:1203-1209.
66. Hogaboom, G.K. and Fedan, J.S. (1981) Biochem. Biophys. Res. Commun.
99:737-744.
67. Jarrett, H. W. and Penni ston, J. 1. (1977) Bi ochem. Bi ophys. Res. Com­
mun. 77:1210-1216.
68. Anderson, J.M., Charbonneau, H., Jones, H.P., McCann, R.O., and Cor­
mier, M.J. (1980) Biochemistry �:3113-3120.
69. Epel, D., Patton, C., Wallace, R.W., and Cheung, W.Y. (1981) Cell
23:543-549.
70. Sheno1ikar, S., Cohen, P.T.W., Cohen, P., Nairn, A.C., and Perry, S.V.
(1979) Eur. J. Biochem. 100:329-337.
71. Delorenzo, R.J., Freedman, S.D., Yohe, W.B., and Maurer, S.C. (1979)
Proc. Natl. Acad. Sci. U.S.A. 76:1838-1842.
72. Kennedy, M.B. and Greengard, P. (1981) Proc. Natl. Acad. Sci. U.S.A.
78:1293-1297.
73. Stewart, A.A., Ingrebritsen, T.S., Mana1an, A., Klee, C.B. and Cohen,
P. (1982) FEBS lett. 137:80-84.
74. Amphlett, G.W., Vanaman, T.C. and Perry, S.V. (1976) FEBS lett.
72:163-168.
75. Dedman, J.R., Potter, J.D. and Means, A.R. (1977) J. Biol. Chern.
252:2437-2440.
76. Wells, J.N. and Hardman, J.G. (1977) Adv. Cyc. Nuc. Res. 8: 119-143.
page 63
77. K1ee, C.B. (1977) Biochemistry �:1017-1024.
78. Teo, T.S. and Wang, J.H. (1973) J. Bio1. Chern. 248:5950-5955.
79. Bender, J .L. and Neer, LJ. (1983) J. Bio1. Chern. 258:2432- 2439.
80. Wolff, J., Cook, G.H., Goldhammer, A.R., and Berkowitz, S.A. (1980)
Proc. Nat1. Acad. Sci. U.S.A. 77:3841-3844.
81. Katada, T., and Ui, M. (1979) J.Biol. Chern. 254:469-479.
82. Burns, D.L., Hewlett, LL., Moss, J., and Vaughn, M. (1983) J. Biol.
Chern. 258:1435-1438.
83. Kakiuchi, S., Sobue, K., Yamazaki, R., Nagao, S., Umeki, S., Nazawa, Y.,
Yazawa, M., and Yagi, K. (1981) J. Biol. Chern. 256:19-22.
84. Jamieson, G.A., Vanaman, T.C. and Blum, J.J. (1979) Proc. Natl. Acad.
Sci. U.S.A. 76:6471-6475.
85. Kudo, S., Muto, Y., Nagao, S., Naka, M., Hidaka, H., Sano, M., and
Nozawa, Y. (1982) FEBS Lett. 149:271-276.
86. Van Eldik, L.J. and Watterson, D.M. (1981) J. Biol. Chern. 256: 4205-
4210.
-
87. Sobue, K., Fugita, M., Muramoto, Y., and Kakiuchi, S. (1980) Biochem.
Int. 1:561-566.
88. Sobue, K., Muramoto, y., Fujita, M., and Kakiuchi, S. (1981) Proc.
Natl. Acad. Sci. U.S.A. 78:5652-5655.
89. Carlin, R.C., Bartelt, D.C. and Siekevitz, P. (1983) J. Cell Biol.
96:443-448.
90 • Gl enney, J. R., Jr. and Weber , K. ( 1980) J. B i 01. Ch em • 255 : 10551-
10554.
-
91. Itano, T., Itano, R. and Penni ston, J. T. (1980) Bi ochem. J. 189: 455-
459.
92. Wolff, D.J., Ross, J.M., Thompson, P.N., Brostrom, M.A., and Brostrom,
C.O. (1981) J. Biol. Chern. 256:1846-1860.
93. Grand, R.J. and Perry, S.V. (1980) Biochemistry 19:227-240.
94. Carnegie, P.R. and Moore, W.J. (1980) in Proteins of the Nervous
System, 2nd edition (Bradshaw, R.A. and Schneider, D.M., eds.) pp.119-
143, Raven Press, New York.
.
95. Burgess, W.H., Schleicher, M., Van Eldik, L.J., and Watterson, D.M.
(1983) in Calcium and Cell Function, vol. 4, (Cheung,W.Y., ed.) pp.209-
261, Academic Press, New York.
page 64
96. Kakiuchi, S. and Sobue, K. (1981) FEBS Lett. 132:141-143.
97. Carlin, R.K., Grab, D.J. and Siekevitz, P. (1981) J. Cell Biol.
89:449-455.
98. Burgess, W.H., Schleicher, M. and Watterson, D.M. (1983) J. Cell
Biol., submitted for publication.
99. Giedroc, D.P., Puett, D., Ling, N., and Staros, J.V. (1983) J. Biol.
Chern. 258:16-19.
100. Van Eldik, L.J. and Burgess, W.H. (1983) J. Biol. Chern., 258:4539-
4547.
101. Grab, D.J., Berzins, K., Cohen, R.S., and Siekevitz, P. (1979) J.
Biol. Chern. 254:8690-8696.
102. Wood, J.G., Wallace, R.W., Whitaker, J.N., and Cheung, W.Y. (1980) J.
Cell Biol. 84:66-76.
103. Moore, B.W. and McGregor, D. (1965) J. Bio1. Chern. 240:1647- 1653.
104. Moore, B.W. (1965) Biochem. Biophys. Res. Commun. �:739-744.
105. Gombos, G., Vincendon, G., Tardy, J., and Mandel ,P. (1966) C.R. Acad.
(Paris) ser.D 263:1533-1535.
106. McEwen, B.S. and Hyden, H. (1966) J. Neurochem. 13:823-833.
107. Uyemura, K., Vincendon, G., Gombos, G., and Mandel, P. (1971) J.
Neurochem. 18:429-438.
108. Dannies, P.S. and Levine, L. (1971) J. Bio1. Chern. 246:6276- 6283.
109. Stewart, J.S. (1972) Biochim. Biophys. Acta 263:178-192.
110. Mahadik, S.P., Korenovsky, A. and Rapport, M.M. (1979) J. ·Neurochem.
33: 763-771.
111. Mani, R.S., Boyes, B.E. and Kay, C.M. (1982) Biochemistry 21: 2607-
2612.
-
112. Isobe, T., Nakajima, T. and Okuyama, T. (1977) Biochim. Biophys. Ac­
ta. 494:222-232.
113. Marshak, D.R., Watterson, D.M. and Van E1dik, L.J. (1981) Proc. Natl.
Acad. Sci. U.S.A. 78:6793-6797.
114. Endo, T., Tanaka, T., Isobe, T., Kasai, H., Okuyama, T. and Hidaka, H'.
(1981) J. Biol. Chern. 256:12485-12489.
115. Seamon, K.B. (1980) Biochemistry �:210-215.
116. Marshak, D.R., Van Eldik, L.J. and Watterson, D.M. (1981) Ann. N.Y.
page 65
Acad. Sci. 356:410-411.
117. Isobe, T., Ishioka, N. and Okuyama, T. (1981) Eur. J. Biochem.
115: 469-474.
118. Calissano, P., Moore, B.W. and Friesen, A. (1969) Biochemistry
8:4318-4326.
119. Mani, R.S., Boyes, B.E. and Kay, C.M. (1982) Biochemistry 21: 2607-
2612.
---
120. Dannies, P.S. and Levine, L. (1971) J. Bio1. Chern. 246:6284-6287.
121. Donato, R. and Michetti, F. (1981) J. Neurochem. 36:1698-1705.
122. Calissano. P. and Bangham, A.D. (1971) Biochem. Biophys. Res. Com­
mun. 43:504-509.
123. Mi chetti , F. , DeRenzi s, G., Donato, R. and Mi ani, N. (1976) Brai n Res.
105:372-375.
124. Baudier, J., Briving, C., Deinum, J., Haglid, K., Sorskog, L. and Wal­
lin, M. (1982) FEBS Letts 147:165-167.
125. Zomzel ey-Neurath, C. and Wa1 ker, W. (1980) in Protei ns of the Nervous
System, 2nd ed. (Bradshaw, R. A. and Schnei der, D. M., eds.) pp. 1-58,
Raven Press, New York.
126. Moore, B.W. (1975) Adv. Neurochem. 1:137-155.
127 • Hi daka, H., Endo, T. , Kawamoto, S. , Yamada, E., Umekawa, H., Tanabe, K.
and Hara, K. (1983) J. Bio1. Chern. 258:2705-2709.
128. Kanamori, M., Endo, T., Shirakawa, S., Sakurai, M. and Hidaka, H.
(1982) Biochem. Biophys. Res. Commun. 108:1447-1453.
129. Honda, F., Katsuki, S. and Sakai, N. (1973) Jap. J. Pharmaco1. Supp1.
23:27.
130. Levin, R.M. and Weiss, B. (1975) Mol. Pharmacol. 13:690-697.
131. Levin, R.M. and Weiss, B. (1975) Mol. Pharmaco1. 12:581-589.
132. Cohen, P., Pi cton, C. and Kl ee, C. B. (1979) FEBS Lett. 104: 25-30.
133 • B a 1 de s s a r i n i, R • J • ( 1980 ) i nTh e Ph a rm a col 0 9 i cal Bas i s 0 f
Therapeutics (Gilman, A.G., Goodman, L.S. and Gilman, A., eds.), pp.
395-418, Macmillan, New York.
134. Levin, R.M. and Weiss, B. (1979) J. Pharmaco1. Exp. Ther. 208: 454-
459.
-
135. Norman, J.A., Drummond, A.H. and Moser, P. (1979) Mol. Pharmaco1.
16:1089-1094.
page 66
136. Roufoga1is, B.D. (1981) Biochem. Biophys. Res. Commun. 98: 607-613.
137. Weiss, B., Prosia1eck, W., Cimino, M., Barnette, M.S., and Wallace,
r.i . (1980) Ann. N.Y. Acad. Sci. 356:319-345.
138. Westhead, E.W. (1972) Methods Enzym. �:401-409.
139. Gabay, S. and Huang, P.C. (1974) in The Phenothiazines and Struc­
turally Related Drugs (Forrest, 1.S., Carr, C.J. and Usdin, L, eds.)
pp. 175-189, Raven Press, New York.
140. Gi esecke, J. and Hebert, H. (1979) Q. Rev. Bi ophys. 12: 263-313.
141. Seeman, P. (1971) Pharmacol. Rev. 24:583-621.
142. Nelson, G.A., Andrews, M.l., and Karnovsky, M.J. (1983) J. Cell.
Bio1. 96:730-735.
143. Ohnishi, S. and McConnell, H.M. (1965) J. Am. Chern. Soc. 87: 2293.
144. Porumb,1. and Slade, LF. (1976) Eur. J. Biochem. 65:21-24.
145. Veronese, F.M., Bevilacqua, R. and Chaiken, I.M. (1979) Mol. Phar­
maco1. 15:313-321.
146. Means, G.E., Sollene, N.P., Mohamed, A. (1982) in Modification of
Protei ns (Feeney, R. E. and Whi taker, J • R. , eds.) pp. 325-346, Ameri can
Chemical Society, Washington, D.C.
147. Snyder, S.H., Banerjee, S.P., Yamamura, H.!. and Greenberg, D. (1974)
Science 184:1243-1253.
148. Clement-Cormier, Y.C., Kebabian, J.W., Petzold, G.L. and Greengard,
P. (1974) Proc. Natl. Acad. Sci. U.S.A. 71:1113-1117.
149. Ba1dessarini, R.J. and Tarsy, D. (1980) in long-Term Effects of
Neuro1eptics (Cattabeni, F., Racagni, G., Spano, P.F., and-Costa, E.,
eds.) pp.451-456, Raven Press, New York.
150. Charbonneau, H. and Cormier, M.J. (1979) Biochem. Biophys. Res. Com­
mun. 90:1039-1047.
151. Jamieson, G.A., Jr., and Vanaman, T.C. (1979) Biochem. Biophys. Res.
Commun. 90:1048-1056.
152. Glenney, J.R,., Jr., Bretscher, A. and Weber, K. (1980) Proc. Nat1.
Acad. Sci. U.S.A. 77:6458-6462.
153. Schubart, U.K., Fleisher, N. and Er1ichman, J. (1980) J. Bio1. Chern'.
255: 11063-11066.
154. Kuo, J.F., Andersson, R.G.G., Wise, B.C., Macker10va, t.., Salomonsson,
r., Brackett, N.L., Katoh, N., Shoji, M. and Wrenn, R.W. (1980) Proc.
Natl. Acad. Sci. U.S.A. 77:7039-7043.
page 67
155. Caroni,P.,Rein1ib,L. andCarafo1i,E. (1980)Proc. Natl. Acad.
Sci. U.S.A. 77:6354-6358.
156. Kuhn, D.M., O'Callaghan, J.P., Juskevich, J. and Lovenberg, W. (1980)
Proc. Nat1. Acad. Sci. U.S.A. 77:4688-4691.
157. Barron, J.T., Barany, M., Barany, K. and Storti, R.V. (1980) J. Biol.
Chern. 255:6238-6244.
158. Krausz, Y., Woll heim, C.G., Siegel, E. and Sharp, G.W.G. (1980) J.
C1in. Invest. 66:603-607.
159. Sheter1ine, P. (1980) Biochem. Biophys. Res. Commun. 93:194-200.
160. Schubart, U.K., Er1ichman, J. and Fleischer, N. (1980) J. Bio1. Chern.
256:4120-4124.
161. White, G.C. and Raynor, S.T. (1980) Thromb. Res. �:279-284.
162. Stull, J.T., B1umentah1, D.K. and Coole, R. (1980) Biochem. Phar­
maco1. 29:2537-2543.
163. Moore, P.B. and Dedman, J.R. (1982) J. Bio1. Chern. 257:9663-9667.
164. Mori, T., Takai, Y., Minakuchi, R., Yu, B. and Nishizuka, Y. (1980) J.
Bio1. Chern. 255:8378-8280.
165. LaPorte, D.C., Wierman, B.M. and Storm, D.R. (1980) Biochemistry
19:3814-3819.
166. Steiner, R.F. and Sternberg, H. (1982) Biopo1ymers �:1411-1425.
167. Volpi, M., Sha'afi, R.I., Epstein, P.M., Andrenyak, D.M. and Fein­
stein, M.B. (1981) Proc. Nat1. Acad. Sci. U.S.A. 78:795-799.
168. Lukas, T.J. and Watterson, D.M. (1983) Biophys. J., �:408a.
169. Hidaka, H., Yamaki, T., Totsuka, T. and Asano, M. (1979) Mol. Phar­
maco1. 15:49-59.
170. Hidaka, H., Yamaki, T., Naka, M., Tanaka, T., Hayashi, H. and
Kobayashi, R. (1980) Mol. Pharmaco1. 17:66-72.
171. Kobayashi, R., Tawata, M. and Hidaka, H. (1979) Biochem. Biophys.
Res. Commun. 88:1037-1045.
172. Hi daka, H. , Asano, M. and Tanaka, T. (1981) Mol. Pharmaco1. 20: 571-
578.
173. Van Eldik, L.J., Grossman A.R., Iverson, D.B., and Watterson, D.M.
(1980) Proc. Nat1. Acad. Sci. U.S.A. 77:1912-1916.
174. Laemm1i, U.K. (1970) Nature 227:680-685.
page 68
175. Hirs, C.H.W. (1967) Methods Enz. 11:59-62.
176. Watterson, 0 .M., Iverson, D. B.
Biochemistry �:5762-5768.
177. K1ee, C.B., 01dewurte1, M.D., Williams, J.F. and lee, J.W. (1981)
Biochem. Intl. 2:485-493.
and Van El dik, L.J. (1980)
178. Hummel, J.P. and Dreyer, W.J. (1962) Biochim. Biophys. Acta 63: 532-
534.
-
179. Rajeswaran, P. and Kirk, P.l. (1962) Bull. Narcotics 14:19.
180. Richman, P.G. and K1ee, C.B. (1978) J. Bio1. Chern. 253:6323- 6326.
181. Watterson, 0 .M., Iverson, D. B. , and Van E1 di k , L.J. (1980) J. Bi ochern.
Biophys. Methods !:139-146.
182. Dorval, G., We1 sh, K. I., and Wi gzell , H. (1975) J. Immunol. Methods
7:237-250.
183. Barany, G. and Merrifield, R.B. (1980) in The Peptides: Analysis,
Synthesi s, Bi 01 ogy, vol. 2 (Gross, E. and Mei enhofer, J., eds.) pp. 1-
284, Academic Press, New York.
184. Audibert, F., Jo1ivet, M., Chedid, L., Arnon, R., and Se1a, M. (1982)
Proc. Natl. Acad. Sci. U.S.A. 79:5042-5046.
185. Watterson, D.M., Burgess, W.H., lukas, T.J., Iverson, D., Marshak,
D.R., Schleicher, M., Erickson, B.W., Fok, K.F., and Van E1dik, l.J.
(1983) Adv. Cyc. Nucl. Res. �:in press.
186. levine, L. and Moore, B.W. (1965) Neurosci. Res. Prog. Bull. 2:18-
22.
-
187. Haan,E.A.,Boss,B.D.,andCowan,W.M. (1982)Proc. Natl. Acad. Sci.
U.S.A. 79:7585-7589.
188. Head, J.F., Masure, H.R., and Kaminer, B. (1982) FEBS letts. 137:71-
74.
-
189. Horowitz, M.G. and Klotz, I.M. (1956) Arch. Biochem. Biophys. 63:77-
86.
-
190. Klotz, I.M. and luborsky, S.W. (1959) J. Am. Chern. Soc. 81:5119-
5124.
191. K10tz,I.M., Burkhard, R.K., and Urquhart, J.M. (1952) J. Am. Chern.
Soc. 74:202-208.
192. K1evitt, R.E., levine, B.A. and Williams, R.J.P. (1981) FEBS lett.
123:25-29.
193. Krebs, J. and Carafol i, E. (1982) Eur. J. Biochem. 124: 619-627.
page 69
194. Scholtan, W. (1955) Kolloid Zeitschrift 142:84-104.
195. Triggle, D.J. (1982) in Calcium Regulation by Calcium Antagonists
(Rahwan, R.G. and Witiak, D.T., eds.) pp. 17-38, American Chemical
Society, Washington, D.C.
page 70
TABLE 1: Amino Acid Compositions of S100a and SIOOS Isolated from
Bovine Brain
SlOOa S100S
moles per residues, no. moles per residues, no.
10,400 9 per molecule 10,507 g per molecule
Aspartic acid 13.2 13 9.9 9
Threonine 3.7 4 3.0 3
Serine 4.1 5 4.5 5
Glutamic acid 14.8 15 19.4 19
Proline 0 0 0 0
Glycine 5.8 6 4.2 4
Alanine 7.4 8 5.2 5
Cystei ne1 1.3 1 2.4 2
Valine 7.2 8 6.3 7
Methionine 2.0 2 2.8 :3
Isoleucine 1.3 1 3.9 4
Leucine 11.2 11 8.3 8
Tyrosine 2.0 2 1.1 1
Phenylalanine 5.1 5 6.9 7
Histidine 2.3 2 4.3 5
Lysine 9.4 9 8.2 8
Tryptophan2 0.7 1 <0.01 0
Arginine <0.06 0 1.3 1
The number of moles was calculated from composition analysis using the
molecular weight calculated from the amino acid sequences (33-34). The
number of residues per molecule were calculated from the amino acid
sequences (33-34).
1 Determined as cysteic acid after performic acid oxidation
2 Determined after hydrolysis in methane sulfonic acid
TABLE 2: Amino Acid COTPositions2of S100S Peptides
Cyanogen Bromide Digestion Trypsin Digestion of Performic
of Carbox�meth�lated S100e Acid Oxidized S100e
2 3 4 7 1 2 3 4 5 9 14
Aspartic cid 3.6 5.5 1.0 2.0 1.2 7.6
Threonine 1.5 1.0 3.0
Serine 1.3 3.2 1.0 1.0 1.2 1.3 2.2
Glutamic cid 3.1 3.9 12.0 1.0 2.0 1.0 1.1 2.0 1.2 12.1
}
Proline
Glycine 0.3 2.6 2.9 0.9 2.9 1.3 2.2
Alanine 2.0 1.1 2.4 2.0 3.0
Cysteine1 0.5 0.6 2.3
Valine 1.2 5.2 2.5 3.6
Methionine N.D.
Isoleucine 1.1 2.9 1.1 2.7
Leucine 1.1 6.8 1.8 1.1 0.9 0.9 1.1 3.8
Tyrosine 1.0 0.7
Phenylalanine 0.9 2.3 1.9 2.4 0.8 5.4
Histidine 2.0 2.9 1.2 1.0 2.8
Lysine 7.9 1.9 4.6 1.8 1.0 0.9 1.9
Arginine 1.1 0.8
Recovery (%) 50 32 21 54 48 49 64 45 79 34 46
Peptide
Assignment3 75-79 80-91 58-74 1-57 21-24 21-24 29-33 30-33 1-5 6-20 34-91
25-26 27-28
1Determined as carboxymethyl cysteine in cyanogen. bromide
fragments and as cysteic acid in trypsin fragments.
2Compositions were calculated as molar ratios
3Peptideassignments are based on the amino acid sequence of bovine brain S100e (33-34).
N.D. ot Determined
TABLE 3: Amino Acid Compositions of Human and Rat S100 Proteins
Human Rat
HI H2 H3 R1 R2
(moles per 10,300g) (moles per 10,300g)
Aspartic acid 12.3 12.6 10.6 10.4 10.7
Threonine 3.6 4.0 3.0 3.9 3.4
Serine 6.1 6.9 4.1 10.8 5.2
Glutamic acid 17.3 19.2 18.8 16.9 17.9
Proline 0 0 0 0 0
Glycine 7.4 5.3 5.1 16.3 5.3
Alanine 6.4 7.2 5.2 5.2 5.0
Cysteine N.D. N.D. N.D. N.D. N.D.
Valine 6.5 3.3 6.0 5.4 6.6
Methionine 2.4 2.9 4.1 2.4 2.3
Isoleucine 1.3 1.5 3.4 3.6 3.4
-
Leucine 7.5 5.9 8.8 6.9 8.4
Tyrosine 1.0 0 1.0 2.3 1.2
Phenylalanine 6.4 6.9 6.2 3.8 7.0
Histidine 3.6 4.4 4.8 2.9 4.8
Lys i ne 9.1 9.4 7.7 5.8 7.4
Tryptophan1 0 0 0 N.D N.D.
Arginine 1.0 1.1 1.0 2.9 1.3
Calculated from composition analysis using a molecular weight of 10,300.
1 Determined after hydrolysis in methane sulfonic acid
N.D. Not Determined
TABLE 4: Chlorpromazine Binding to Calmodulins
Binding Ratio
(Moles drug bound/mole protein)









TABLE 5: Amino Acid Compositions of Dictyostelium Calmodulin Peptides

























































































44 61 85 94
75-106 107-148 1-37 38-74
38.:.106
Compositions were calculated by molar ratios.
Peptide assignments are based on the amino acid sequence of bovine brain
calmodulin (32).
N.D. Not Determined
TABLE 6: Amino Acid Compositions of Calmodulin Peptides from Submaxillary
Gland Protease Digest
28 (91-106)* 48 (107-148) * 50 (1-37)* 63 (1-90)*
Aspartic Acid 2.7 3 6.9 7 5.5 4 12.8 13
Threonine 0.1 0 3.6 3 4.8 5 9.0 9
Serine 1.2 1 0 0 2.6 1 3.0 3
Glutamic acid 1.5 1 10.9 9 9.0 7 19.0 17
Proline 0 0 0 0 0 0 N.D. 2
Glycine 2.3 2 3.7 3 5.0 3 6.8 6
Alanine 2.1 2 2.2 2 3.5 3 7.5 7
Valine 1.1 1 4.3 4 2.0 1 2.5 2
Methionine 0.1 0 3.8 4 1.3 1 4.3 5
Isoleucine 1.0 1 2.3 2 2.3 2 5.5 5
Leucine 1.1 1 2.4 2 3.3 3 6.5 6
Tyrosine 1.0 1 1.2 1 0.7 0 0 0
Phenylalanine 1.0 1 1.2 1 2.8 3 6.2 6
Histidine 0.3 0 1.0 1 0.4 0 0 0
Trimethyllysine 0 0 0.9 1 0.4 0 0 0
Lysine 1.0 1 1.0 1 3.0 3 5.0 5
Arginine 0.4 1 0.5 2 1.5 1 1.6 4
Recovery (% ) 45 55 15 66
Compositions of peptides were calculated by molar ratios
* Number of residues per molecule for regions of calmodulin (shown in parentheses)
from the amino acid sequence of bovine brain calmodulin.
N.D. Not Determined














TABLE 8: Chlorpromazine Binding to Fragments of Bovine
Brain Calmodulin
Binding Ratio
(Moles drug bound/mole peptide)













FIGURE 1: Comparison of the amino acid sequences of calmodulin from four
speci es: bovi ne brai n (32, 95), Reni 11 a reni formi s (44), spi nach
( 47 -49), and Tetrahymena pyriformi s ( 46) . The ami no ac i d
residues of bovine brain calmodulin are numbered according to
Watterson et al. (32). Blank spaces indicate amino acid residues
i denti cal to those found in bovi ne brai n cal modul in, and #
represents a reported deletion. Positions which have been
postulated to be calcium ligands (12) are marked with an asterisk
(*), and positions postul ated (12) to be on the internal aspect of
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FIGURE 2: Comparison of the known amino acid sequence differences in the
carboxy terminal domain of calmodulin from Chlamydomonas rein­
hardt i i (50) and Di ctyoste 1 i urn di scoi deum. The sequence deter­
mination for Dictyostel ium calmodul in is documented in the Appen­
di x . The symbols and the sequences of other cal modul ins are the
same as in Figure 1.
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FIGURE 3: Ami no aci d sequences of SlOOa and SlOOS from bovi ne brai n (33-34).
The ami no aci d resi dues of SlOOa are numbered and the sequence of
S100S is aligned according to Isobe and Okuyama (33). Residues 1-
88 of S100S are a1 igned with residues 2-89 of S100a, and residues
89-91 of S100S are a1 i gned wi th resi dues 91-93 of S100a. The sym­
bol # corresponds to a gap inserted in the sequence of S100S for
the purpose of a1 i gnment. The asteri sks (*) represent ami no aci d
residues postulated (12,30,33-34) to be calcium ligands, and bars
( _) i ndi cate ami no aci d res i dues postu1 ated (12, 30,33-34) to be
on the i nterna 1 aspect of the a-he 1 ices. The 1 etter B denotes an
unidentified blocking group on the amino terminus of S100a.
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FIGURE 5: Polyacrylamide gel electrophoresis of fractions from anion ex­
change (A) and a ffi ni ty-based adsorpti on (B) chromatography of a
preparation of bovine brain.
A. Al; quots (3. 5 u 1) of fracti ons from chromatoqraphy of bovi ne
brain extract on diethylaminoethyl-Sephadex A-50 were analyzed
by electrophoresis on a 15% (w/v) potyecryt ami de gel in the
presence of 0.1% (w/v) sodi urn dodecyl sul fate and 1 mM EGTA. The
protein retained hy the resin were eluted with a grartient (2
liters) of 0.2 M to 0.7 M NaCl as described in the text, and 200
fractions of 10 ml were collected. The Coomassie blue staininq
pattern is shown for several f"ractions, with the fraction numher
indicated. The lane marked S contains a mixture of bovine brain
calmodul in and S100(3 for standards. The arrows mark the positions
of the standards: calmodul in (CaM) and S100(3 (S100). Two pool s of
fractions were collected containinq S10n (fractions 45-75) anrt
calmodulin (fractions 76-100).
�
B. The pool of fractions containing S100 from the anion exchange
chromatography described above was subjected to chromatoqraphy
on phenothiazine-Sepharose conjugates as described in the text.
Aliquots of material eluted by various buffers from the
phenothiazine-Sepharose conjugates were analyzed by elec­
trophoresis on a 15% (w/v) polyacrylamide gel in the presence of
0.1% (w/v) sodium dodecyl sulfate and 1 mM EGTA. The Coomassie
bl ue stai ni ng pattern is shown: 1 anes 1,8, chi cken qi zzard cal­
modulin; lanes 2,7 molecular weight markers (phosphorylase b,
94,000; bovine serum albumin, 67,000; ovalbumin, 43,000; car­
bonic anhydrase, 30,000; soybean trypsin inhibitor, 20,100; a­
lactalbumin, 14,400); lane 3, elution with calcium buffer (10 mM
Tri s-HC1, pH 8.0, 1 mM MgC12 ' 2 mM CaC12 ' 1 mM 2-mercap­
toethanol); lane 4, elution wfth calcium buffer containinq 0.4 M
NaCl; lane 5, elution with chelator buffer (10 mM Tris-Htl, pH
R.O, 1 mMMgC12, 2 mM EGTA) containing 0.4 M NaCl; lane s , elution












FIGURE 6: Separation of bovine brain S100a and S100S by reverse phase
chromatography on �80ndapak phenyl resin. The material eluted
from phenothi azi ne-Sepharose conj ugates wi th EGTA and NaCl (1 ane
5, Fi gure 58) , was subj ected to chromatography on a col umn (0.78 x
30 cm) of �80ndapak phenyl resin equil ibrated in 80% (v/v) 0.01 M
potassium phosphate, pH 6.1, 0.5 mM EGTA, and 20% (v/v)
acetonitrile. Calmodulin was eluted by changing the solvent com­
postion to 28% (v/v), S100a eluted with 32% (v/v) acetonitrile,
and S100S el uted wi th 36% (v /v) acetoni tril e. The ordi nate shows
the absorbance of the effl uent at 235 nm as the ampl i tude of the
detector response in millivolts. The abscissa shows the reten­
ti on time (RT) in mi nutes. The retenti on times of the peaks are
marked. Peaks corresponding to proteins are indicated: CaM, cal­
modul in; S100a; and S100S. The peaks occuri ng at 9.90 and 10.91
conta i ned res i dual tri s (hydroxymethyl) ami nomethane, excess EG­
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FIGURE 7: Ultravi 01 et absorpti on spectra of S100a (top) and S100t3 (bottom).











































FIGURE 8: Separation of S100S peptides by reverse phase chromatography.
Carboxymethylated S100S was digested with cyanogen bromide and
performic acid oxidized SlOOp was digested with trypsin as
described in the text. The digests were applied to a column (0.94
x 25 cm) of octadecyl s i 1 anyl res in (ODS) equi 1 i brated in 95% (v /v)
0.01 N HCl and 5% (v/v) acetonitrile. Peptides were eluted by in­
creas i ng the amount of acetoni tri 1 e in the mobile phase at a flow
rate of 2 ml/min. The ordinates show the absorbance of the ef­
fl uent at 215 nm as the ampl itude of the detector response in mil­
livolts, and the abscissas show the retention time (RT) in
minutes. The retention times of the peaks are marked, and the
fractions which were collected for analysis are numbered.
A, carboxymethylated S100� digested with cyanogen bromide;
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FIGURE 9: Radi oimmunoassay of 5100 protei ns from human brai n. Competi ti ve
inhibition radioimmunoassays were performed with serum 2 from
rabbit 616 as described in the text using 125I-S100a as antigen.
The ordi nate expresses the degree of i nhibiti on as a percentage of
the radi oacti vi ty bound in the absence of competi ng protei n. The
abscissa shows the nanograms of competing protein:
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FIGURE 10: Immunol ogi cal responses of rabbi ts 512 (0) and 513 (.) to immuni za­
tion with performic acid oxidized bovine brain S100S. Direct
radioimmunoassays were performed using 125I_S100S as antigen ac­
cording to procedures described in the text. The ordinate ex­
presses the amount of anti gen bound as a percentage of the
radioactivity added to the assay. The abscissa shows the time in
days following the initial injection. The days on which the rab­
bits received injections are indicated by open arrows, and the
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FIGURE 11: Immunol ogi cal responses of rabbits 615 (.) and 616 (0) to immuni za-
tions with performic acid oxidized bovine brain S100a. Direct
radioimmunoassays were performed using 125I-S100a as antigen ac­
cording to procedures described in the text. The ordinate ex­
presses the amount of anti gen bound as a percentage of the
radi oacti vi ty added to the assays. The absci ssa shows the time in
days following the initial injection. The days on which the rab­
bits received injections are indicated by open arrows, and the
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FIGURE 12: Competitive radioimmunoassays using serum 1 (solid lines) and
serum 5 (broken 1 ine) from rabbit 512 using 125I-S100S as antigen.
The ordi nate expresses the degree of i nhi bi ti on as a percentage of
the amount of radi oacti vi ty bound in the absence of competi ng an­
tigen. The abscissa shows the picomoles of competing proteins:
bovine brain S100S (.,.); bovine brain S100a (o,�); bovine brain
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FIGURE 13: Competitive inhibition radioimmunoassays using serum 4 of rabbit
616 and 125I_S100a as anti gen. The ordi nate expresses the degree
of i nhi bi ti on as a percentage of the amount of radi oacti vi ty bound
in the absence of competing antigen. The abscissa shows the
picomoles of competing proteins: bovine brain S100a (.) and


















FIGURE 14: Immunol ogi cal responses of rabbi ts 35 (0) and 36 (.) to immuni za­
tion with bovine brain S100S. Direct radioimmunoassays were per­
formed using 125I-S100S as described in the text. The ordinate
expresses the amount of antigen bound as a percentage of the
radi oacti vi ty added to the assays. The absci ssa shows the time in
days following the initial injection. Days on which the rabbits
recei ved i njecti ons are i ndi cated by open arrows, and the days on
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FIGURE 15: Competitive inhibition radioimmunoassays using serum 1 of rabbit
36 and 125I-S100S as anti gen. The ordi nate expresses the degree
of i nhi bi ti on as a percentage of the amount of radi oacti vi ty bound
in the absence of competi ng protei n The absci ssa shows the
picomoles of competing antigens: bovine brain S100S (.), and
bovine brain S100a (0).
o 0 000o w � � N,...















FIGURE 16: Immunological responses of rabbits 13 (.,.) and 14 (o,�) to im­
munization with peptide ME13B-ovalbumin conjugates. Direct
radioimmunoassays were performed using 125I-S100B (.,0) or 1251_
S100a (.,�) as described in the text. The ordinate expresses the
amount of anti gen bound as a percentage of the amount of radi oac­
ti vi ty added to the assays. The days on whi ch the rabbi ts recei ved
injections are indicated by open arrows, and the days on which
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FIGURE 17: Binding of 125I-calmodulin to immobilized phenothiazines. 1251_
calmodul in was incubated with phenothiazine-Sepharose con­
j ugates for 60 mi nutes at room temperature in buffer conta i ni ng 10
mM Tris-HC1, pH 7.4, 2 mM CaC12 ' 1 mM MgC12 ' 1 mM 2-mercap­
toethanol. Following incubation, the unbound radioactivity was
removed and the bound radi oacti vi ty was el uted as descri bed in the
text. The ordi nate expresses the amount of radi oacti vi ty bound as
a percentage of the amount of radi oacti vi ty added to each assay.
The results are the means of duplicate determinations, and the
















FIGURE 18: Separation of 125I-calmodul in peptides by reverse phase
chromatography. Bovine brain calmodulin was iodinated (180)
using lactoperoxidase and digested with trypsin as described in
the text. The di gest was appl i ed to a col umn (D. 94 x 25 cm) of oc­
tadecylsilanyl resin (ODS) equilibrated in 95% (v/v) 0.01 N Hel
and 5% (v/v) acetonitrile, and the peptides were eluted by in­
creasing the amount of acetonitrile in the mobile phase. Frac­
tions of 2 ml (1 minute) were collected, and the radioactivity in
each fraction was measured. The ordinate shows the amount of
radi oacti vi ty, and the absci ssa shows the retenti on time in
mi nutes. The arrows i ndi cate the retenti on time for the




































FIGURE 19: Competitive inhibition of 125I-calmodulin binding to
phenothiazine-Sepharose conjugates by calcium modulated
proteins. The ordinates express the degree of inhibition as a
percentage of the radi oacti vi ty bound in the absence of competi ng
protein.
A. Competing proteins were bovine brain calmodul in (.); chicken
gizzard calmodulin (.); spinach calmodulin (0); and barley cal­
modul i n (�). Resul ts are the means of dupl i cate determi nati ons,
and the range of values was <6%.
B. Competi ng protei ns were: bovi ne brai n cal modul in (.); rabbi t
skeletal muscle troponin C (0); bovine brain 51008 (x); and carp
parvalbumin (A). Results are the means of duplicate determina­
tions with the range of val ues indicated when >2%. Resul ts
similar to those shown for parvalbumin were obtained for chicken


















FIGURE 20: Calcium dependent adsorptionof bovine brain S100S to
phenothiazine-Sepharose conjugates. In separate experimetns,
purified bovine brain S100S was applied to and eluted from a
column (0.65 x 3.0 cm) containing phenothiazine-Sepharose con­
j ugates. Effl uents were coll ected and analyzed by el ec­
trophoresis on a 18% (w/v) polyacrylamide gel containing 0.1%
(w/v) sodi urn dodecyl sul fate. In the fi rst experiment (l anes 1-
3), the col umn was equi 1 i brated wi th cal ci urn buffer (10 mM Tri s­
HCl , pH 8.0, 1 mM MgC12 ' 1 mM 2-mercaptoethanol , and 2 mM CaC12 ) ;
in the second experiment (lanes 4-6), the column was equilibrated
wi th chel ator buffer (10 mM Tri s-HCl , pH 8.0, 1 rnM MgC12 ' 1 rnM 2-
mercaptoethanol, and 2 rnM EGTA). Three milliliters each of the
following solutions was passed through the calcium-equilibrated
column: calcium buffer, lane 1; calcium buffer containing 0.2 M
NaCl, lane 2; chel ator buffer containing 0.2 M NaCl, lane 3. The
chel ator-equi 1 i brated col urnn was el uted wi th 3 ml each of the fol-
1 owi ng sol uti ons: chel ator buffer, 1 ane 4; chel ator buffer con­





FIGURE 21: Equil ibrium binding of chlorpromazine to bovine brain calmodul in
using the method of Hummel and Dreyer (178). Bovine brain cal­
modulin (1.25 nmol) was dissolved in buffer (50 mM Tris-HC1, pH
7.4, 150 mM NaCl, 1 mM CaC12 ' 9.3 �M chlorpromazine) and appl ied
to a column (0.5 x 30 cm) of BioGel P-6 equilibrated in the same
buffer at 0.3 ml/min. The ordinate expresses the absorbance of
the effl uent at 254 nm expressed as the ampl i tude of the response
of the detector in mi 11 i vol ts. The absci ssa shows the retenti on























FIGURE 22: External calibration of chlorpromazine binding to bovine brain
calmodulin. Samples containing known amounts of chlorpromazine
above that in the buffer (50 mM Tri s-HCl , pH 7.4, 150 mM NaCl, 1 mM
CaC12 ' 12.5 lJM chl orpromazi ne) were appl i ed to a col umn (0.5 x 30
cm) of Bi oGel P6 equi 1 i brated in the same buffer. The absorbance
of the effl uent was measured at 254 nm, and the areas of the peaks
corresponding to the samples of drug were integrated as described
in the text. The areas of these peaks are shown (.). The ordinate
expresses the area of the peaks in vol t-seconds, and the absci ssa
shows the nanomoles of chlorpromazine in the samples above that in
the buffer. The line shown was calculated by linear regression
analysis, and the correlation coefficient was >0.99. An e­
quilibrium binding experiment using 1.25 nmol bovine brain cal­
modul in was performed as descri bed in the text and in Fi gure 21-
The area of the trough is shown (0) wi th the range of val ues from
duplicate determinations. The dashed line indicates the inter­
polated value for the number of nanomoles of chlorpromazine
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FIGURE 23: Internal calibration of chlorpromazine binding to calmodulin.
Five samples of bovine brain calmodulin (1.25 nmo1) were dis­
sol ved in buffer (50 mM Tri s-HC1 , pH 7 .4, 150 mM NaCl , 1 mM CaC12 '
12.5 �M chlorpromazine). An aliquot of excess chlorpromazine
(0,1,2,4, or 6 nmo1 above the 12.5 �M chlorpromazine in the
buffer) was added to each sample, and the samples were fi 1 tered on
a column (0.5 x 30 cm) of BioGe1 P6 at a flow rate of 0.3 m1/min.
The ordi nate shows the absorbance of the effl uent expressed as the
amp1 i tude of the detector response in vol ts for the fi ve experi­
ments. The absci ssa shows the retenti on time (RT) in mi nutes. The
amount of excess chlorpromazine added to the sample are as fol­
lows: curve a, 0 nmol ; curve b, 1 nmo1 ; curve c, 2 nmo1 ; curve d, 4
















FIGURE 24: Graphical representation of the internal calibration of chlor­
promazine binding to bovine brain calmodulin. The areas of the
troughs (negative areas) or peaks (positive areas) of unbound
chl orpromazi ne for the experiments in Fi gure 23 are shown (.) as a
function of the number of nanomoles of excess chlorpromazine
added to each sampl e. The ordi nate expresses the areas in vol t­
seconds. The solid line was calculated by linear regression
analysi s, and the carrel ati on coeffi ci ent was >0.99. The dashed
line indicates the interpolated value for the amount of excess
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FIGURE 25: Equil ibrium binding of chlorpromazine by bovine brain calmodul in
as a function of chlorpromazine concentration. The binding of
chlorpromazine to calmodulin was measured using the method of
Hummel and Dreyer (178) in buffer containing calcium (50 mM Tris­
HC1, pH 7.4, 150 mM NaCl , 1 mM CaC12 ), (.), or in buffer containing
magnesium (50 mM Tris-HC1, pH 7.4, 150 mM NaCl, 4 mM MgC12 ' 1 mM
EGTA) , (0). The ordi nate expresses the number of mol es of chlor­
promazi ne bound per mol e of protei n. The absci ssa shows the con­
centrati on of chl ropromazi ne in the buffer. Resul ts shown are the
means of values calculated from external and internal calibra­
ti ons. The range of val ues is shown when >5%. For experiments in
whi ch the bi ndi ng rati 0 was 1 ess than 0.4 mol es of chl orpromazi ne
per mol e of protei n , the resul ts shown are the means of dupl i cate
determinations calculated from external calibration, and the































FIGURE 26: Separation of peptides of Dictyostelium calmodulin by reverse
phase chromatography. Dictyostelium calmodulin was digested
with mouse submaxillary gland protease and applied to a column
(0.94 x 25 cm) of octadecyl s i 1 anyl res in (ODS) equi 1 i brated in 5%
(v/v) 0.01 N Hel and 95% (v/v) acetonitrile. The peptides were
eluted by increasing the amount of acetonitrile in the mobile
phase as descri bed in the text. The ordi nate shows the absorbance
of the effl uent at 215 nm expressed as the ampl i tude of the detec­
tor response in mi 11 i vol ts. The absci ssa shows the retenti on time
(RT) in mi nutes foll owi ng appl i cati on of the sampl e. The numbered
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FIGURE 27: Binding of chlorpromazine by calcium modulated proteins. E­
quil ibrium binding experiments were performed using the method of
Hummel and Dreyer (178) in buffer conta in i ng calc i urn (50 mM Tri s­
HCl , pH 7 .4, 150 mM NaCl , and 1 mM CaC12 ) as descri bed in the text.
The number of moles of chlorpromazine bound per mole of protein
are shown for CaM, bovine brain calmodulin; TnC, rabbit skeletal
muscle troponin C; S100S, bovine brain S100S; S100a, bovine brain
S100a; Parv. , carp parval bumi n; PAO-CaM, performi c aci d oxi di zed
bovine brain calmodulin. For each protein, results are shown for
three chlorpormazine concentrations: 9-10 �M (left), 45-50 �M
(center), and 100 �M (r; ght). The resul ts shown are the means of
duplicate determinations with the range of values <0.2 moles of
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FIGURE 28: Competitive inhibition of 125I-calmodulin binding to
phenothiazine-Sepharose conjugates by digests of calmodulin.
The ordi nate expresses the degree of i nhi bi ti on as a percentage of
the amount of radioactivity bound in the absence of competing
protein. The abscissa shows the amount of competing protein:
bovine brain calmodul in (.), chicken gizzard calmodul in digested




































FIGURE 29: Competitive inhibition of 125I-calmodulin binding to
phenothi azi ne-Sepharose conj ugates by di gests of ci traconyl ated
calmodul in. The ordinate expresses the degree of inhibition as a
percentage of the amount of radi oacti vi ty bound in the absence of
competing protein. The abscissa shows the amount of competing
protein: bovine brain calmodulin (.); citraconylated bovine
brain calm�dulin digested with trypsin (a); spinach calmodulin
(...); citraconylated spinach calmodul in digested with trypsin (6).
The resul ts shown are the means of dupl i cate determi nati ons, and






































FIGURE 30: Competitive inhibition of 125I-calmodulin binding to
phenothiazine-Sepharose conjugates by calmodulin digested with
mouse submaxillary gland protease. The ordinate expresses the
degree of i nhi bi ti on as a percentage of the radi oacti vi ty bound in
the absence of competi ng protei n. The absci ssa shows the amount
of competing protein: bovine brain calmodulin (.) and bovine
brain calmodulin digested with mouse submaxillary gland protease
(o). The resul ts shown are the means of dupl i cate determi nati ons,
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FIGURE 31: Competitive inhibition of 125I-calmodulin binding to
phenothiazine-Sepharose conjugates by synthetic peptides. The
ordi nate expresses the degree of i nhi bi ti on as a percentage of the
amount of radi oacti vi ty bound in the absence of competi ng
protein. The abscissa shows the amount of competing protein:
bovine brain calmodul in (.); peptide FF25 (.); peptide AF20 (0);
and pepti de AE21 (.). Ami xture of pepti des AE21 (12 nmol ) and FF25
(10 nmol ) is al so shown (0). The resul ts are the means of dupl i cate
determinations, and the range of values was <10%. The amino acid
sequences of the synthetic peptides are shown in Table 7.
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FIGURE 32: Competitive inhibition of 125I-calmodulin binding to
phenothiazine-Sepharose conjugates by performic acid oxidized
calmodulin. The ordinate expresses the degree of inhibition as a
percentage of the radi oacti vi ty bound in the absence of competi ng
protein. The abscissa shows the amount of competing protein:
bovine brain calmodulin (.), and performic acid oxidized bovine



































FIGURE 33: Acti vati on of cycl i c nucl eoti de phosphodi esterase by chi cken gi z­
zard calmodulin (.) and bovine brain calmodulin digested with
mouse submaxillary gland protease (0). The ordinate shows the
amount of AMP produced duri ng an i ncubati on for 6 mi nutes at 30°C
with 60 1-Ig of enzyme preparation as described by Watterson et al .
(181). The abscissa shows the amount of calmodulin or calmodulin
di gest added to the assays. The resul ts are the means of dupl i cate



















FIGURE 34: Effects of trypsin treatment on calmodulin activities. Samples
(0.1 mg) of bovine brain calmodulin were treated with various
amounts of tryps in for 14 hours at 37°C as descri bed in the text.
The treated protei n was tested for its abi 1 i ty to acti vate cycl i c
nucleotide phosphodiesterase (0), and to inhibit 125I-calmodul in
bi ndi ng to phenothi azi ne-Sepharose conj ugates (.). The ordi nate
expresses the acti vi ty of each sampl e as a percentage of the ac­
tivity of bovine brain calmodul in which was incubated under iden­
tical conditions without trypsin. The activities were measured
with an amount of protein equal to the amount of control cal­
modulin necessary to give full enzyme activation (0.3 nmol) or
full inhibition of 125I-calmodulin binding to the immobilized
phenothi azi nes. The absci ssa shows the amount of trypsi n in the
digestion. The results shown are the means of duplicate deter­
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FIGURE 36: Effect of chlorpromazine on 125I-calmodulin binding to proteins
in a gel overlay experiment. Polyacrylamide gel electrophoresis
in the presence of sodi urn dodecyl sul fate was performed as
described in the text on four identical gels with the following
samples: A, molecular weight markers (phosphorylase b, 94,000;
bovine serum albumin, 67,000; ovalbumin, 43,000; carbonic anhy­
drase, 30,000; soybean trypsin inhibitor, 20,100; a.-lactalbumin,
14,400); B, chicken gizzard myosin 1 ight chain kinase (3 �g); C,
rabbi t skel etal muscl e phosphoryl ase b kinase (5 �g); 0, chi cken
-embryo f.ibroblast post-microsomal supernatant fraction (13 �g);
E, chi cken embryo fi brob 1 ast mi crosoma 1 fracti on (12 uq}. Over-
1 ay procedures were performed as descri bed in the text. For each
gel, the top panel shows the Coomassie blue staining pattern and
the lower panel shows the correspondi ng autoradi ogram depi cti ng
the binding of 125I-calmodul in. Before incubation with the gel,
125I-calmodul in was incubated for 30 mi nutes at room temperature
in 50 mM Tris-HC1, pH 7.4, 150 mM NaCl with the following addi­
tions: gel 1, 4mM EOTA; gel 2,1 mM CaC12 ; gel 3, 1 mM CaC12 and 10
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APPENDIX: Automated Sequencer Determination of Peptides
Peptides were isolated from digests of Oictyostelium calmodulin and
bovine brain S100a by reverse phase chromatography on octadecylsilanyl
resin as described in the text. The peptides were dissolved in water or
0.01 N ammonium bicarbonate, and the protein concentration was deter­
mined by amino acid analysis.
An al i quot (1300-2300 pmol) of each pepti de wa� subjected to automated
amino acid sequencer determination with an Applied 8iosystems 470A in­
strument usi ng the standard program supp1 i ed by the manufacturer. Frac­
ti ons from the sequencer were dri ed and di ssol ved in methanol for
analysi s . Phenyl i sothi ocyany1-ami no aci ds were i denti fi ed by hi gh per­
formance liquid chromatography on a column (0.41 x 25 cm) containing oc­
tadecy1si1anyl resin (Zorbax ODS, DuPont) operated at 60°C. The elution
sol vents consi sted of A: 50 mM sodi urn acetate, pH 5.0 and 8:
acetonitrile. The PTH-amino acids were eluted at a flow rate of 1.5
ml Imi n, and the absorbance of the effl uent was moni tored at 254 nm. The
foll owi ng programmed steps were used: 0 mt n., %8 10; 8 mi n. � %8 40; 12
min., %8 40; 13 min., %8 55; 16 min., %8 60.
TABLE A1: Automated Sequencer Determination? of
Peptides from Bovine Brain SIOOS
Peptide 58-74: 1780 pmol Peptide 6-20: 1310 pmol
C�cle Residue pmol Cycl e Residue pmol
1 Glutamic acid 1345 1 Alanine 408
2 Threonine 308 2 Valine 218
3 Leucine 400 3 Valine 211
4 Aspartic acid 305 4 Alanine 200
.5 Serine 42 5 Leucine 150
6 Aspartic acid 107 6 Isoleucine 163
7 Glycine 20 7 Aspartic acid 410
8 Aspartic acid 38 8 Valine 137
9 Glycine 20 9 Phenylalanine
10 Glutamic acid 18 10 Histidine
11 Glutamine
12 Tyrosine






PTH- amino acids obtained at each cycle were identified by liquid
chromatography as described in the Appendix. The recoveries of PTH-Serine
and PTH-Threonine were variable, and these residues were also identified
as their dehydro forms. The last 6 residues of peptide 6-20 were identi­
fied qualitatively.
TABLE A2: Automated Sequencer Determination of Peptide 17 from
Dictyostelium Calmodulin1
Cycle Residue pmoles Cycle Residue pmoles
1 Histidine 683 19 Isoleucine 119
2 Valine 908 20 Arginine
3 Methionine 749 21 Glutamic acid ,85
4 Threonine 204 22 Alanine 115
5 Serine 62 23 Aspartic acid 94
6 Leucine 650 24 Leucine 103
7 Glycine 392 25 Aspartic acid 76
8 Glutamic acid 497 26 Glycine 84
9 Lysine 311 27 Aspartic acid 58
10 Leucine 587 28 Glycine 84
11 Threonine 294 29 Glutamine 50
12 Asparagine 366 30 Valine 56
13 Glutamic acid 371 31 Asparagine 44
14 Glutamic acid 333 32 Tyrosine 43
15 Valine 282 33 Glutamic acid 29
16 Aspartic acid 234 34 Glutamic acid 18
17 Glutamic acid 190 35 Phenylalanine 5
18 Methionine 214 36 Valine 12
1 Peptide 17 (2300 pmoles) was subjected to automated sequence analysis, and
the PTH-amino acids obtained at each cycle were identified by liquid chroma­
tography as described in the text. Recoveries of PTH-Serine and PTH �Threonine
were variable and were also identified qualitatively as their dehydro forms.
PTH-Arginine was identified qualitatively.
ABBREVIATIONS
ACM acetaminocarboxymethyl




BCCP biotin carboxyl carrier protein
Boc tert-butyloxycarbonyl
cAMP cyclic adenosine 31-51 monophosphate
cGMP cyclic guanosine 31-51 monophosphate
DNA deoxyribonucleic acid
OTT dithiothreitol
EOTA ethylenediamine tetraacetic acid
EGTA ethyleneglycol bis(s-aminoethylether)-N,N,NI ,NI-tetraacetic acid
GTP guanosine 51-triphosphate
Met(O) methionine sulfoxide
NAO nicotinamide adenine dinucleotide
PTH phenylthiohydantoin
SEM standard error of the mean
TPCK L-l-(p-toluenesulfonyl)amido-2-phenylethylchloromethyl ketone
Tris tris(hydoxymethyl)aminomethane
ABBREVIATIONS FOR AMINO ACIDS
A Ala Alanine
C Cys Cysteine
0 Asp Aspartic acid
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